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Integrative and comparative genomic
analyses identify clinically relevant pulmonary
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The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their
molecular characteristics. Through machine learning and multi-omics factor analysis,
we compare and contrast the genomic proﬁles of 116 pulmonary carcinoids (including 35
atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers.
Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify
atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and
27%, respectively. We identify therapeutically relevant molecular groups of pulmonary car-
cinoids, suggesting DLL3 and the immune system as candidate therapeutic targets;
we conﬁrm the value of OTP expression levels for the prognosis and diagnosis of these
diseases, and we unveil the group of supra-carcinoids. This group comprises samples with
carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC,
further supporting the previously proposed molecular link between the low- and high-grade
lung neuroendocrine neoplasms.
https://doi.org/10.1038/s41467-019-11276-9 OPEN
Correspondence and requests for materials should be addressed to L.F.-C. (email: fernandezcuestal@iarc.fr). #A full list of authors and their afﬁliations
appears at the end of the paper.
NATURE COMMUNICATIONS |         (2019) 10:3407 | https://doi.org/10.1038/s41467-019-11276-9 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
According to the WHO classiﬁcation from 2015
1 and
a recent IARC-WHO expert consensus proposal2,
pulmonary carcinoids are low-grade typical and
intermediate-grade atypical well-differentiated lung neuroendo-
crine tumours (LNETs) that belong to the group of lung neu-
roendocrine neoplasms (LNENs), which also includes the high-
grade and poorly differentiated small-cell lung cancer (SCLC) and
large-cell neuroendocrine carcinomas (LCNEC). Pulmonary
carcinoids are rare malignant lesions, annual incidence of which
has been increasing worldwide, especially at the advanced stages3.
Pulmonary carcinoids account for 1–2% of all invasive lung
malignancies: typical carcinoids exhibit good prognosis, although
10-23% metastasise to regional lymph nodes, resulting in a 5-year
overall survival rate of 82–100%. The prognosis is worse for
atypical carcinoids, with 40–50% presenting metastasis, reducing
the 5-year overall survival rate to 50%.
Contrary to pulmonary carcinoids, most of which are eligible
for upfront surgery at the time of diagnosis3, LCNEC and SCLC
require upfront aggressive, multimodal treatment for most of the
patients. Owing to these differences in clinical management and
prognosis, the accurate diagnosis of these diseases is critical.
However, there is still no consensus on the optimal approach for
their differential diagnosis;2 the current criteria, based on mor-
phological features and immunohistochemistry, are imperfect and
inter-observer variations are common, especially when separating
typical from atypical carcinoids4, as well as atypical carcinoids
from LCNEC in small biopsies5. Ki67 protein immune-reactivity
has been suggested as a good marker of prognosis in LNENs as a
whole, and for the differential diagnosis between carcinoids and
SCLC6,7, whereas this marker does not faithfully follow the
deﬁning histological criteria of typical and atypical carcinoids4.
The difﬁculties in ﬁnding good markers to separate these diseases
might be due to the limited amount of comprehensive genomic
studies available for SCLC, LCNEC, and typical carcinoids, and
the complete lack of such studies for atypical carcinoids8. In
addition, such studies would also be needed to validate the recent
proposed molecular link between pulmonary carcinoids and
LCNEC9,10.
In this study, we provide a comprehensive overview of the
molecular traits of LNENs—with a particular focus on the
understudied atypical carcinoids—in order to identify the
mechanisms underlying the clinical differences between typical
and atypical carcinoids, to understand the suggested molecular
link between pulmonary carcinoids and LCNEC, and to ﬁnd new
candidates for the diagnosis and treatment of these diseases.
Results
Data. We have generated new data (genome, exome, tran-
scriptome, and methylome) for 63 pulmonary carcinoids
(including 27 atypical) and 20 LCNEC. In order to perform
comparative analyses, we have reanalysed published data for 74
pulmonary carcinoids11, 75 LCNEC12, and 66 SCLC13,14. Taken
together, we have performed multi-omics integrative analyses on
116 pulmonary carcinoids (including 35 atypical), 75 LCNEC,
and 66 SCLC (Supplementary Fig. 1 and Supplementary Data 1).
Molecular groups of pulmonary carcinoids and LCNEC. We
performed an unsupervised analysis of the expression and
methylation data of the LNENs (i.e., 110 pulmonary carcinoids
and 72 LCNEC) using the Multi-Omics Factor Analysis imple-
mentation of the group factor analysis statistical framework
(Software MOFA)15 (MOFA LNEN; Fig. 1a and Supplementary
Figs. 2 and 3). We identiﬁed ﬁve latent factors explaining more
than 2% of the variance in at least one data set, and among them,
three latent factors provided consistent groups of samples with
similar expression and methylation proﬁles (i.e., clusters). MOFA
latent factors one (LF1) and two (LF2) explained a total of 45%
and 34% of the variance in methylation and expression, respec-
tively, and were both associated with survival (Supplementary
Fig. 4). Using consensus clustering on these two latent factors
(which explained most of the variation and thus carried most of
the biological signal; Supplementary Figs. 5–7 and Supplementary
Data 2–3), we identiﬁed three clusters, each of them enriched for
samples of one of the three histopathological types (Fig. 1a).
Cluster Carcinoid A was enriched for typical carcinoids (75%;
Fisher’s exact test p-value < 2.2 × 10−16); cluster Carcinoid B was
enriched for atypical carcinoids (54%; Fisher’s exact test p-value
< 2.2 × 10−16) and male patients (79%; Fisher’s exact test p-value
= 1.6 × 10−9); and cluster LCNEC included 92% of the histo-
pathological LCNEC (Fisher’s exact test p-value < 2.2 × 10−16).
Note that clustering based on LF1 to LF5, weighted by their
proportion of variance explained, leads to the exact same clusters
(Supplementary Fig. 8).
To assess whether the current histopathological classiﬁcation
could be improved by the combination of molecular and
morphological characteristics, we undertook a machine-learning
(ML) analysis. To do so, we combined the predictions from two
independent random forest classiﬁcations, based on only-
expression or only-methylation data. Using two independent
models allowed the inclusion of samples for which only one of
these data sets was available, thus maximising the power of
subsequent analyses (Fig. 1b and Supplementary Fig. 9 for an
alternative analysis based on both ‘omic data sets simultaneously,
but restricted to fewer samples). In order to avoid overﬁtting the
data, we performed a leave-one-out cross-validation, with feature
ﬁltering and normalisation learned from the training set and
applied to the test sample. To identify intermediate proﬁles, we
deﬁned a prediction category (unclassiﬁed) for samples that had a
probability ratio between the two most probable classes close to
one. We present in Fig. 1b the results for a cutoff ratio of 1.5, and
show in Supplementary Fig. 10 the robustness of our results with
regard to this ratio. Ninety-six per cent of the carcinoids
predicted as typical by the ML were in cluster Carcinoid A
(Fig. 1a). Similarly, the majority of ML-predicted atypical
carcinoids (87%) belonged to cluster Carcinoid B.
We selected the ML-prediction groups with >10 samples
(gathering the unclassiﬁed samples in one single group) and
compared their overall survival using Cox’s proportional hazard
model (coloured groups in Fig. 1b). The machine learning trained
on the histopathology stratiﬁed atypical carcinoids into two
prognostic groups: the good-prognosis group (atypical reclassiﬁed
as typical, in pink in Fig. 1b, c) with a 10-year overall survival
similar to that of samples conﬁrmed by ML as typical carcinoids
(in black in Fig. 1b, c; 88% and 89%, respectively; Wald test p-
value= 0.650); and the bad-prognosis group (atypical predicted
as atypical, in red in Fig. 1b, c) with a 10-year overall survival
similar to that of samples conﬁrmed by ML as LCNEC (in blue in
Fig. 1b, c; 27% and 19% respectively; Wald test p-value= 0.574;
see also Supplementary Fig. 11). Machine-learning analyses based
on other features -combined expression and methylation data
(Supplementary Fig. 9), MOFA latent factors (Supplementary
Fig. 12A), and Principal component analyses (PCA) principal
components explaining more than 2% of the variance (Supple-
mentary Fig. 12B)- led to qualitatively similar results.
Atypical carcinoids with LCNEC molecular characteristics. Six
atypical carcinoids clustered with LCNEC in the MOFA LNEN
(supra-carcinoids; Fig. 1a). Consistent with this clustering, this
group displayed a survival similar to the other samples in the
LCNEC cluster (10-year overall survival of 33% and 19%,
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Fig. 1 Multi-omics (un)supervised analyses of lung neuroendocrine neoplasms. a Multi-omics factor analysis (MOFA) of transcriptomes and methylomes
of LNEN samples (typical carcinoids, atypical carcinoids, and LCNEC). Point colours correspond to the histopathological types; coloured circles correspond
to predictions of histopathological types by a machine learning (ML) algorithm (random forest classiﬁer) outlined in b; ﬁlled coloured shapes represent the
three molecular clusters identiﬁed by consensus clustering. The density of clinical variables that are signiﬁcantly associated with a latent factor (ANOVA
q-value < 0.05) are represented by kernel density plots next to each axis: histopathological type for latent factor 1, sex and histopathological type for latent
factor 2. b Confusion matrix associated with the ML predictions represented on a. The different colours highlight the prediction groups considered in the
survival analysis and the colours for machine learning are consistent between panel b and upper panel c. Black represents typical carcinoids predicted as
typical, pink represents atypical carcinoids predicted as typical, red represents atypical carcinoids predicted as atypical, and blue represents LCNEC
samples predicted as LCNEC. For the unclassiﬁed category, the most likely classes inferred from the ML algorithm are represented by coloured arcs (black
for typical, red for atypical, blue for LCNEC, and light grey for discordant methylation-based and expression-based predictions). c Kaplan–Meier curves of
overall survival of the different ML predictions groups (upper panel) and histopathological types (lower panel). Upper panel: colours of predicted groups
match panel b. Lower panel: black-typical, red-atypical, blue-LCNEC. Next to each Kaplan–Meier plot, matrix layouts represent pairwise Wald tests
between the reference group and the other groups, and the associated p-values; 0.01≤ p < 0.05, 0.001≤ p < 0.01, and p < 0.001 are annotated by one, two,
and three stars, respectively. Data necessary to reproduce the ﬁgure are provided in Supplementary Data 1
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respectively; Wald test p-value= 0.574; Fig. 2a). The observed
molecular link appears to be between supra-carcinoids and
LCNEC rather than with SCLC, as shown by PCA and MOFA
including expression data for 51 SCLC (Supplementary Figs. 6
and 13, respectively).
These samples originated from three different centres (two
from each), and included two previously published samples
(S01513 and S01522)11, implying that this observation is unlikely
to be the result of a batch effect. The limited number of supra-
carcinoids did not allow to explore aetiological links; however, it
is of note that one of them (LNEN005) belonged to a patient with
professional exposure to asbestos (which is known to cause
mesothelioma)16 (Table 1), and the tumour harboured a splicing
BAP1 somatic mutation (a gene frequently altered in mesothe-
lioma)17. This sample showed the highest mutational load
(37 damaging somatic mutations; Supplementary Data 4). Gene
set enrichment analyses (GSEA) of mutations in the hallmarks of
cancer gene sets18,19, showed a signiﬁcant enrichment for the
hallmark evading growth suppressor (q-value= 0.0213; Fig. 2b
and Supplementary Data 5), while the hallmark genome
instability and mutation was signiﬁcant only at the 10% false
discovery rate (FDR) threshold (q-value= 0.0970; Fig. 2b and
Supplementary Data 5). We had access to the Haematoxylin and
Eosin (H&E) stain for three of these supra-carcinoids, on which
the pathologists discarded misclassiﬁcations with LCNEC, SCLC,
or mesothelioma in the case of the asbestos-exposed BAP1-
mutated sample (Fig. 2c and Table 1).
While generally similar to LCNEC, and albeit based on small
numbers, the supra-carcinoids appeared to have nonetheless
some distinct genomic features based on genome-wide expression
and methylation proﬁles (Fig. 2d). Supra-carcinoids displayed
higher levels of immune checkpoint genes (both receptors and
ligands; Fig. 2e), and also harboured generally higher expression
levels of MHC class I and II genes (Fig. 2e and Supplementary
Fig. 14). Interestingly, the interferon-gamma gene—a prominent
immune-stimulator, in particular of the MHC class I and II genes
—also showed high-expression levels in these samples (Supple-
mentary Fig. 14). The differences in immune checkpoint gene
expression levels between groups were not explained by the
amount of inﬁltrating cells, as estimated by deconvolution of gene
expression data with software quanTIseq (Fig. 2f, left panel).
However, supra-carcinoids contained the highest levels of
neutrophils (greater than the 3rd quartile of the distributions of
neutrophils in the other groups; Fig. 2f, right panel). Permutation
tests showed that these levels were signiﬁcantly higher than in
other carcinoid groups and in SCLC, but not than in LCNEC
(Supplementary Fig. 15). Concordantly, GSEA showed that
MOFA LNEN LF1 (separating LCNEC and supra-carcinoids
from the other carcinoids) was signiﬁcantly associated with
neutrophil chemotaxis and degranulation pathways (Supplemen-
tary Data 6). By contrast, no such association was observed in the
MOFA performed only on carcinoids and SCLC samples
(Supplementary Figs. 6C and 13C and Supplementary Data 6).
Mutational patterns of pulmonary carcinoids. In a previous
study, mainly including typical carcinoids, we detected MEN1,
ARID1A, and EIF1AX as signiﬁcantly mutated genes11. We also
found that covalent histone modiﬁers and subunits of the SWI/
SNF complex were mutated in 40% and 22.2% of the cases,
respectively. Genomic alterations in these genes and pathways
were also seen in the new samples included in this study (Fig. 3a,
Supplementary Fig. 16, and Supplementary Data 4). Apart from
the above-mentioned genes, ATM, PSIP1, and ROBO1 also
showed some evidence, among others, for recurrent mutations in
pulmonary carcinoids (Fig. 3a). In addition to point mutations
and small indels, the ARID2, DOT1L, and ROBO1 genes were also
altered by chimeric transcripts (Fig. 3b). MEN1 was also inacti-
vated by genomic rearrangement in a carcinoid sample
with a chromothripsis pattern affecting chromosomes 11 and 20
(Fig. 3c). The full lists of somatically altered genes, chimeric
transcripts, and genomic rearrangements are presented in Sup-
plementary Data 4, 7, and 8, respectively. Of note, MEN1
mutations were signiﬁcantly associated with the atypical carcinoid
histopathological subtype (Fisher’s exact test p-value= 0.0096), as
well as MOFA LNEN LF2.
Altered pathways in pulmonary carcinoids. The third latent
factor from the MOFA LNEN accounted for 8% and 6% of the
variance in expression and methylation, respectively, but unlike
LF1 and LF2, LF3 was not associated with patient survival
(Supplementary Fig. 4). The molecular variation explained by LF3
appeared to capture different molecular proﬁles within cluster
Carcinoid A (Supplementary Fig. 13B). We therefore undertook
an additional MOFA restricted to pulmonary carcinoid samples
only (MOFA LNET; Fig. 4a and Supplementary Fig. 17). This
MOFA identiﬁed ﬁve latent factors that explained at least 2% of
the variance in one data set. As expected, the ﬁrst two latent
factors of the MOFA LNET were highly correlated with LF2 and
LF3 from the MOFA LNEN, respectively, (Pearson correlation
>0.96; Supplementary Fig. 13B), and explained 41% and 35% of
the variance in methylation and expression, respectively. Inte-
grative consensus clustering using LF1 and LF2 of the MOFA
LNET identiﬁed three clusters (Supplementary Fig. 18): cluster
Carcinoid A1 and cluster Carcinoid A2, that together correspond
to the samples in cluster Carcinoid A of the MOFA LNEN, plus
the supra-carcinoids; and cluster Carcinoid B (as for the clus-
tering of LNEN samples, a clustering based on LF1-LF5 weighted
by their proportion of variance explained, led to the exact same
clusters; Supplementary Fig. 8). LF2 was associated with age, with
cluster Carcinoid A1 enriched for older patients ((60, 90]
years old) and cluster Carcinoid A2 enriched for younger patients
((15, 60] years old).
We applied GSEA to identify the pathways associated with the
different latent factors. We found signiﬁcant associations with the
immune system and the retinoid and xenobiotic metabolism
pathways (Supplementary Data 6). Numerous Gene Ontology
(GO) terms and KEGG pathways were related to the immune
system, immune cell migration, and infectious diseases. The GO
terms and KEGG pathways related to immune cell migration
included leucocyte migration, chemotaxis, cytokines, and
interleukin 17 signalling. In particular, the expression of all
β-chemokines (including CCL2, CCL7, CCL19, CCL21, CCL22,
known to attract monocytes and dendritic cells)20 (Supplemen-
tary Data 6), and all CXC chemokines (such as IL8, CXCL1,
CXCL3, and CXCL5, known to attract neutrophils)21, were
positively correlated with MOFA LNEN LF1 (separating
pulmonary carcinoids from LCNEC) and negatively correlated
with MOFA LNET LF2 (separating clusters Carcinoid A1
and A2).
The different LNET clusters did not differ in their total
amounts of estimated proportions of immune cells, but they did
differ in their composition (Supplementary Fig. 19): cluster
Carcinoid A (particularly A1) was signiﬁcantly enriched in
dendritic cells, and cluster Carcinoid B, in monocytes (Fig. 4b,
upper panel). As monocytes can differentiate into dendritic cells
in a favourable environment22, we assessed the levels of LAMP3
and CD1A dendritic-cells markers23, and found that samples in
cluster Carcinoid A1 presented high-expression levels of these
genes (Fig. 4b, lower panel), implying that this cluster was indeed
enriched for dendritic cells. We pursued this further by assessing
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the CD1A protein levels by immunohistochemistry (IHC) in an
independent series of pulmonary carcinoids, and found that 60%
of them (12 out of 20) were enriched in CDA1-positive dendritic
cells, conﬁrming the presence of dendritic cells in a subgroup of
pulmonary carcinoids (Fig. 4c and Supplementary Data 9).
Regarding the retinoid and xenobiotic metabolism pathways
(e.g., elimination of drugs and environmental pollutants), the
main genes driving the correlation with MOFA latent factors
were the phase II enzymes involved in glucuronosyl-transferase
activity (Supplementary Data 6), but also the phase I cytochrome
P450 (CYP) proteins. These pathways were positively correlated
with MOFA LNEN LF2 (separating LNEN clusters A and B) and
negatively correlated with MOFA LNET LF1 (separating LNET
clusters A1 and A2 from cluster B). Indeed, we found that
samples in cluster Carcinoid B were characterised by high levels
of the CYP family of genes, and a very strong expression of
several UDP glucuronosyl-transferases UGT genes (median
FPKM= 4.6 in UGT2A3 and 28.1 in UGT2B genes; Fig. 4d),
which contrasts with the low levels in other carcinoids (median
FPKM= 0 for both UGT2A3 and UGT2B; Fig. 4d), LCNEC
(median FPKM= 0 and 1.2 for UGT2A3 and UGT2B; Supple-
mentary Fig. 20) and SCLC (median FPKM= 0 and 0.3 for
UGT2A3 and UGT2B; Supplementary Fig. 20).
Molecular groups of pulmonary carcinoids. We explored the
molecular characteristics of each cluster from the MOFA LNET
based on their core differentially expressed coding genes (core-
DEGs, the expression levels of which deﬁned a given group of
samples), corresponding promoter methylation proﬁles (Fig. 5a
and Supplementary Data 10), and their somatic mutational pat-
terns (Figs. 3a and 4a). To achieve this goal, we computed the
DEGs in all pairwise comparisons between a focal group and the
other groups, and then deﬁned core-DEGs as the intersection of
the resulting gene sets. We show in Supplementary Fig. 21 that
core-DEGs are almost exclusively a subset of the DEGs between
the focal group and samples from all other groups taken together.
We correlated the gene expression and promoter methylation
data of the core-DEGs to identify genes, which expression could
be mainly explained by their methylation patterns (Fig. 5a).
One of the top correlations was found for HNF1A and HNF4A
homeobox genes (Supplementary Fig. 22), which were strongly
downregulated in cluster Carcinoid A1 samples (Supplementary
Fig. 23). In addition, the promoter regions of these genes also
harboured core-DMPs (differentially methylated positions) of
cluster Carcinoid A1, indicating that their methylation proﬁle is
speciﬁc of this cluster (Supplementary Data 11). These two genes
have been reported as having a role in the transcriptional reg-
ulation of ANGPTL3, CYP, and UGT genes24, and could thus
explain the differential expression of these genes between the
clusters. Samples in cluster Carcinoid A1 were also characterised
by high-expression levels of the delta like canonical Notch ligand
3 (DLL3, 75% with FPKM > 1) and its activator the achaete-scute
family bHLH transcription factor 1 (ASCL1) (Fig. 5a and Sup-
plementary Data 10), similar to SCLC and LCNEC (Fig. 5b);
however, the expression levels of NOTCH genes did not differ
between the different groups (Supplementary Fig. 24). The supra-
carcinoids were negative for DLL3 expression (Fig. 5b), and had
generally high-expression levels of NOTCH1-3 (Supplementary
Fig. 24). We additionally tested the DLL3 protein levels in the
aforementioned independent series of 20 pulmonary carcinoids
and found 40% (eight out of 20) with relatively high expression of
DLL3 (Fig. 4d and Supplementary Data 9), while in the
other 12 samples DLL3 was strikingly absent (Fig. 4d and Sup-
plementary Data 9). Furthermore, we found a correlation
between the protein levels of DLL3 and CD1A (Pearson test
p-value= 0.00034; Supplementary Fig. 25), providing additional
evidence for the existence of a DLL3+ CD1A+ subgroup of
carcinoids. Core-DEGs in cluster Carcinoid A2 included the
low levels of SLIT1 (slit guidance ligand 1; 97% with FPKM <
0.01), and ROBO1 (roundabout guidance receptor 1; 56% with
FPKM < 1) (Fig. 5a, b and Supplementary Data 10). This cluster
also contained the four samples with somatic mutations in the
eukaryotic translation initiation factor 1A X-linked (EIF1AX)
gene (Fig. 4a). Concordantly, samples with EIF1AX mutations
had signiﬁcantly higher coordinates on the MOFA LNET LF2
(t-test p-value= 0.0342).
Table 1 Characteristics of supra-carcinoids
LNEN005 LNEN012 LNEN021 LNEN022 S01513 S01522
Classiﬁcation
Histopathology Atypical Atypical Atypical Atypical Atypical Atypical
Morphological
characteristics
Carcinoid morph. 2 mitoses/2
mm2 No necrosis
Carcinoid morph. 2 mitoses/2
mm2 No necrosis
LCNEC morph. 4 mitoses/2
mm2 No necrosis
NA NA NA
Machine learning LCNEC LCNEC Unclassiﬁed Unclassiﬁed Atypical Unclassiﬁed
Clinical data
Sex Male Female Female Female Male Male
Age at diagnosis 80 70 83 58 58 63
TNM Stage IB IIIC IA1 IIB IIIA IV
Overall survival
(months)
144.6 111.7 29.8 36.1 59 7
Epidemiology
Smoking status Former NA NA NA Never Current
Other known
exposure
Asbestos NA NA NA NA NA
Multi-omics data
Data available WES, RNAseq, Epic 850K RNAseq Epic 850K Epic 850K WGS, RNAseq WES,
Epic 850K
Cluster
MOFA LNEN
LCNEC LCNEC LCNEC LCNEC LCNEC LCNEC
Cluster
MOFA LNET
Carcinoid A1 Carcinoid A1 Carcinoid A1 Carcinoid A1 Carcinoid A1 Carcinoid A1
Selected
mutated genes
JMJD1C, KDM5C, BAP1 NA NA NA DNAH17 TP53
Mean FPKM of IC
genesa
8.12 10.32 NA NA 3.15 NA
MKI67 FPKM 2.6 7.3 NA NA 1.9 NA
FPKM refers to Fragments Per Kilobase per Million reads. The median FPKM of immune checkpoint (IC) genes was calculated based on the genes included in Fig. 2e, excluding HLA genes because of
their very large expression levels
aIC genes median FPKM values for pulmonary carcinoids, LCNEC and SCLC are 1.0, 3.5, and 3.2, respectively
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As expected based on Fig. 4d, several UGT genes were core-
DEGs of cluster Carcinoid B (Fig. 5a). Also, accordingly with the
worse survival of patients in this cluster (Fig. 2a), these samples
were also characterised by the expression of angiopoietin like 3
(ANGPTL3, 90% with FPKM > 1), and the erb-b2 receptor
tyrosine kinase 4 (ERBB4, 67% with FPKM > 1) (Fig. 5b). This
cluster was also characterised by the universal downregulation of
orthopedia homeobox (OTP; 90% with FPKM < 1), and NK2
homeobox 1 (NKX2-1; 90% FPKM < 1) (Fig. 5b). Interestingly,
the SCLC-combined LCNEC sample (S00602) that clustered with
the pulmonary carcinoids in the MOFA LNEN (Fig. 1a) was the
only LCNEC in our series harbouring high-expression levels of
OTP (290.26 FPKM vs. 9.89 FPKM for the 2nd highest within
LCNEC, the median for LCNEC being 0.22 FPKM). UGT genes,
ANGPTL3, and ERBB4 were also core-DEGs of cluster B samples
when compared to LNEN clusters Carcinoid A and LCNEC
(Supplementary Data 12), which indicates that their expression
levels also signiﬁcantly differed from that of LCNEC. Cluster
Carcinoid B included all observed MEN1 mutations, which is
consistent with the fact that samples with MEN1 mutations had
signiﬁcantly lower coordinates on the MOFA LNET LF1 (t-test
p-value= 7 × 10−6; Fig. 4a). Nevertheless, mutations in this gene
did not explain the poorer prognosis of this group of samples
compared to other LNET (logrank p-value > 0.05; Supplementary
Fig. 26). To gain some insights into what might be driving the bad
prognosis of cluster Carcinoid B samples, we performed a GSEA
of mutations in hallmarks of cancer gene sets18,19; while clusters
Carcinoid A1 and A2 were not enriched for any hallmark of
cancer, cluster Carcinoid B was signiﬁcantly enriched for genes
involved in evading growth suppressor, sustaining proliferative
signalling, and genome instability and mutation at the 5% FDR
(Fig. 5c). We also performed a Cox regression with elastic net
regularisation based on the core-DEGs of this cluster; the model
selected eight coding genes explaining the overall survival, OTP
being one of them (Fig. 5d and Supplementary Data 13). Further
supporting their prognostic value, we found that the expression of
four of these genes was signiﬁcantly different between the good-
and the poor-prognosis atypical carcinoids based on the machine-
learning predictions (Fig. 1c, upper panel and Supplementary
Fig. 27).
Finally, we also checked the MKI67 expression levels in the
different molecular groups and found relatively low levels in the
clusters Carcinoids A1, A2, and B (78% with FPKM < 1) and high
levels in the supra-carcinoids (FPKM > 1 in the three samples). As
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Fig. 3 Mutational patterns of pulmonary carcinoids. a Recurrent and cancer-relevant altered genes found in pulmonary carcinoids by WGS and WES.
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inter-chromosomic rearrangement between genes MEN1 and SOX6. Upper panel: copy number as a function of the genomic coordinates on chromosomes
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Fig. 4 Multi-omics unsupervised analysis of lung neuroendocrine tumours. a Multi-omics factor analysis (MOFA) of transcriptomes and methylomes
restricted to LNET samples (pulmonary carcinoids). Design follows that of Fig. 1a; ﬁlled coloured shapes represent the three molecular clusters (Carcinoid
A1, A2, and B) identiﬁed by consensus clustering. The position of samples harbouring mutations signiﬁcantly associated with a latent factor (ANOVA
q-value < 0.05) are highlighted by coloured triangles on the axes. b Upper panel: boxplots of the proportion of dendritic cells in the different molecular
clusters (Carcinoid A1, A2, and B) and the supra-carcinoids, estimated from transcriptomic data using quanTIseq (Methods). The permutation test q-value
range is given above each comparison: q-value < 0.001 is annotated by three stars. Lower panel: boxplots of the expression levels of LAMP3 (CDLAMP) and
CD1A. c DLL3 and CD1A immunohistochemistry of two typical carcinoids: case 6 (DLL3+ and CD1A+), and case 10 (DLL3- and CD1A-). Upper panels:
Hematoxylin & Eosin Saffron (H&E) stain. Middle panels: staining with CD1 rabbit monoclonal antibody (cl EP3622; VENTANA), where arrows show
positive stainings. Lower panels: Staining with DLL3 assay (SP347; VENTANA). d Expression levels of genes from the retinoid and xenobiotic metabolism
pathway—the most signiﬁcantly associated with MOFA latent factor 1—in the different molecular clusters. Upper panel: schematic representation of the
phases of the pathway. Lower panel: boxplot of expression levels of CYP2C8 and CYP2C19 (both from the CYP2C gene cluster on chromosome 10),
UGT2A3, and the total expression of UGT2B genes (from the UGT2 gene cluster on chromosome 4), expressed in fragments per kilobase million (FPKM)
units. In all panels, boxplot centre line represents the median and box bounds represent the inter-quartile range (IQR). The whiskers span a 1.5-fold IQR or
the highest and lowest observation values if they extend no further than the 1.5-fold IQR. Data necessary to reproduce the ﬁgure are provided in
Supplementary Data 1, 4, 9, and in the European Genome-phenome Archive
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expected, LCNECs and SCLCs carried high levels of this gene
(FPKM > 1 in 99% and 92% of the samples, respectively).
Although the levels of MKI67 for each of the clusters were
different, further analyses showed that MKI67 expression levels
alone were not able to accurately separate good- from poor-
prognosis pulmonary carcinoids (Supplementary Fig. 11B, C).
An overview of the different molecular groups of pulmonary
carcinoids and their most relevant characteristics is displayed in
Fig. 6.
Discussion
Lung neuroendocrine neoplasms are a heterogeneous group of
tumours with variable clinical outcomes. Here, we characterised
and contrasted their molecular proﬁles through integrative ana-
lysis of transcriptome and methylome data, using both machine-
learning (ML) techniques and multi-omics factor analyses
(MOFA). ML analyses showed that the molecular proﬁles could
distinguish survival outcomes within patients with atypical car-
cinoid morphological features, splitting them into patients with
good typical-carcinoid-like survival and patients with a clinical
outcome similar to LCNEC. Overall, out of the 35 histopatholo-
gically atypical carcinoids, ML reclassiﬁed 12 into the typical
category.
Unsupervised MOFA and subsequent gene-set enrichment
analyses unveiled the immune system and the retinoid and
xenobiotic metabolism as key deregulated processes in pulmonary
carcinoids, and identiﬁed three molecular groups—clusters—with
clinical implications (Fig. 6). The ﬁrst group (cluster A1) pre-
sented high inﬁltration by dendritic cells, which are believed to
promote the recruitment of immune effector cells resulting in a
strongly active immunity25. Samples in cluster A1 showed over-
expression of ASCL1 and DLL3. The transcription factor ASCL1
is a master regulator that induces neuronal and neuroendocrine
differentiation. It regulates the expression of DLL3, which
encodes an inhibitor of the Notch pathway26. Overexpression of
ASCL1 and DLL3 is a characteristic of the SCLC of the classic
subtype26 and of type-I LCNEC12. We validated the expression of
DLL3 in an independent series of 20 pulmonary carcinoids
assessed by immunohistochemistry (IHC; 40% positive). The fact
that we found a correlation between the protein levels of DLL3
and CD1A (a marker of dendritic cells also assessed by IHC in
this series; 60% positive) provides orthogonal evidence to support
the existence of this molecular group. Phase I trials have provided
evidence for clinical activity of the anti-DLL3 humanised
monoclonal antibody in high–DLL3-expressing SCLCs and
LCNECs27, and additional clinical trials are ongoing in other
cancer types.
The second group (cluster A2) harboured recurrent somatic
mutations in EIF1AX, and showed downregulation of the SLIT1
and ROBO1 genes. SLIT and ROBO proteins are known to be
axon-guidance molecules involved in the development of the
nervous system28, but the SLIT/ROBO signalling has also been
associated with cancer development, progression, and metastasis.
Pulmonary neuroendocrine cells (PNEC) represent 1% of the
total lung epithelial cell population29, they reside isolated
(Kultchinsky cells) or in clusters named neuroepithelial bodies
(NEBs), and are believed to be the cell of origin of most lung
neuroendocrine neoplasms30. In the normal lung, it has been
shown that ROBO1/2 are expressed, exclusively, in the PNECs,
and that the SLIT/ROBO signalling is required for PNEC
assembly and maintenance in NEBs31. In cancer, this pathway
mainly suppresses tumour progression by regulating invasion,
migration, and apoptosis, and therefore, is often downregulated
in many cancer types28. More speciﬁcally, the SLIT1/ROBO1
interaction can inhibit cell invasion by inhibiting the SDF1/
CXCR4 axis, and can attenuate cell cycle progression by
destruction of β-catenin and CDC4228. Potential clinical avenues
to this ﬁnding exist, especially the ongoing development of
CXCR4 inhibitors.
The third molecular group (cluster B) was enriched in
monocytes and depleted of dendritic cells, and had the worst
median survival. Even in the presence of T cell inﬁltration, this
immune contexture suggests an inactive immune response,
dominated by monocytes and macrophages with potent immu-
nosuppressive functions, and almost devoid of the most potent
antigen-presenting cells, dendritic cells, suggesting dendritic cell-
based immunotherapy as a therapeutic option for this group of
samples32. Cluster B was also characterised by recurrent somatic
mutations in MEN1, the most frequently altered gene in pul-
monary carcinoids and pancreatic NETs33, which is in line with
the common embryologic origin of pancreas and lung.MEN1 was
inactivated by genomic rearrangement due to a chromothripsis
event affecting chromosomes 11 and 20 in one of our samples.
This observation, together with two additional reported cases
involving chromosomes 2, 12, and 1311, and chromosomes 2, 11,
and 2034, respectively, suggest that chromothripsis is a rare but
recurrent event in pulmonary carcinoids. Interestingly, MEN1
mutations did not have a clear prognostic value in our series.
Regarding the above-mentioned deregulation of the retinoid and
xenobiotic metabolism in pulmonary carcinoids, samples in
cluster B presented high levels of UGT and CYP genes. In line
with previous studies35,36, these samples also harboured low levels
of OTP, which gene expression levels were correlated with sur-
vival in the ML predictions. High levels of ANGPTL3 and ERBB4
were also detected in this group of samples, representing candi-
date therapeutic opportunities. ANGPTL3 is involved in new
blood vessel growth and stimulation of the MAPK pathway37.
This protein has been found aberrantly expressed in several types
Fig. 5Molecular groups of pulmonary carcinoids. a Heatmaps of the expression of core differentially expressed genes of each molecular cluster, i.e., genes
that are differentially expressed in all pairwise comparisons between a focal cluster and the other clusters. Green bars at the right of each heatmap indicate
a signiﬁcant negative correlation with the methylation level of at least one CpG site from the gene promoter region. The colour scale depends on the range
of q-value (q) and squared correlation estimate (R²) of the correlation test. b Boxplots of the expression levels of selected cancer-relevant core genes, in
fragment per kilobase million (FPKM) units, where centre line represents the median and box bounds represent the inter-quartile range (IQR). The
whiskers span a 1.5-fold IQR or the highest and lowest observation values if they extend no further than the 1.5-fold IQR. c Characteristic hallmarks of
cancer in each molecular cluster (Carcinoid A1 without the supra-carcinoids, A2, and B), LCNEC, and SCLC. Coloured concentric circles correspond to the
molecular clusters. For each cluster, dark colours highlight signiﬁcantly enriched hallmarks (Fisher’s exact test q-value < 0.05). The mutated genes
contributing to a given hallmark are listed in the boxes. Recurrently mutated genes are indicated in brackets by the number of samples harbouring a
mutation. d Survival analysis of pulmonary carcinoids based on the expression level of eight core genes of cluster Carcinoid B. The genes were selected
using a regularised GLM on expression data. For each gene, coloured lines correspond to the Kaplan–Meier curve of overall survival for individuals with a
high (green) and low (orange) expression level of this gene. Cutoffs for the two groups were determined using maximally selected rank statistics
(Methods). The percentage of samples in each group is represented above each Kaplan–Meier curve and the logrank test p-value is given in bottom right
for each gene. Data necessary to reproduce the ﬁgure are provided in Supplementary Data 5, 10, and in the European Genome-phenome Archive
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of human cancers37. Similarly, overexpression of the epidermal
growth factor receptor ERBB4, which induces a variety of cellular
responses, including mitogenesis and differentiation, has also
been associated with several cancer types38,39.
For many years, it has been widely accepted that the lung well-
differentiated NETs (typical and atypical carcinoids) have unique
clinico-histopathological traits with no apparent causative rela-
tionship or common genetic, epidemiologic, or clinical traits with
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the lung poorly differentiated SCLC and LCNEC3. While mole-
cular studies have sustained this belief for pulmonary carcinoids
vs. SCLC11,13,14, the identiﬁcation of a carcinoid-like group of
LCNECs10,12, the recent observation of LCNEC arising within a
background of pre-existing atypical carcinoid40, and a recent
proof-of-concept study supporting the progression from pul-
monary carcinoids to LCNEC and SCLC9, suggest that the
separation between pulmonary carcinoids and LCNEC might be
more subtle than initially thought, at least for a subset of patients.
Our study supports the suggested molecular link between pul-
monary carcinoids and LCNEC, as we have identiﬁed a subgroup
of atypical carcinoids, named supra-carcinoids, with a clear car-
cinoid morphological pattern but with molecular characteristics
similar to LCNEC. In our series, the proportion of supra-
carcinoids was in the order of 5.5% (six out of 110 pulmonary
carcinoids with available expression/methylation data); however,
considering the intermediate phenotypes observed in the MOFA
LNEN, the exact proportion would need to be conﬁrmed in larger
series. We found high estimated levels of neutrophil inﬁltration in
the supra-carcinoids. For both supra-carcinoids and LCNEC (but
not SCLC), the pathways related to neutrophil chemotaxis and
degranulation, were also altered. Neutrophil inﬁltration may act
as immunosuppressive cells, for example through PD-L1
expression41. Indeed, the supra-carcinoids also presented levels
of immune checkpoint receptors and ligands (including PDL1
and CTLA4) similar—or higher—than those of LCNEC and
SCLC, as well as upregulation of other immunosuppressive genes
such as HLA-G, and interferon gamma that is speculated to
promote cancer immune-evasion in immunosuppressive
environments42,43. If conﬁrmed, this would point to a therapeutic
opportunity for these tumours since strategies aiming at
decreasing migration of neutrophils to tumoral areas, or
decreasing the amount of neutrophils have shown efﬁcacy in
preclinical models44. Similarly, immune checkpoint inhibitors,
currently being tested in clinical trials, might also be a therapeutic
option for these patients.
Overall, although preliminary, our data suggest that supra-
carcinoids could be diagnosed based on a combination of
morphological features (carcinoid-like morphology, useful for the
differential diagnosis with LCNEC/SCLC) and the high expres-
sion of a panel of immune checkpoint (IC) genes (LCNEC/SCLC-
like molecular features, useful for the differential diagnosis with
other carcinoids); the levels of IC genes, such as PD-L1, VISTA,
and LAG3, could also be used to drive the therapeutic decision for
patients harbouring a tumour belonging to this subset of very
aggressive carcinoids. Nevertheless, due to the very low number
of supra-carcinoids identiﬁed so far (n= 6), follow-up studies are
warranted to comprehensively characterise these tumours from
pathological and molecular standpoints, to evaluate the immune
cell distribution, and to establish if the diagnosis of these supra-
carcinoids can be undertaken in small biopsies. Finally, the cur-
rent classiﬁcation only recognises the existence of grade-1 (typi-
cal) and grade-2 (atypical) well-differentiated lung NETs, while
the grade-3 would only be associated with the poorly differ-
entiated SCLC and LCNEC; however, in the pancreas, stomach
and colon, the group of well-differentiated grade-3 NETs are well
known and broadly recognised45. Whether these supra-carcinoids
constitute a separate entity that may be the equivalent in the lung
of the gastroenteropancreatic, well-differentiated, grade-3 NETs
will require further research.
In summary, this study provides comprehensive insights into
the molecular characteristics of pulmonary carcinoids, especially
of the understudied atypical carcinoids. We have identiﬁed three
well-characterised molecular groups of pulmonary carcinoids
with different prognoses and clinical implications. Finally, the
identiﬁcation of supra-carcinoids further supports the already
suggested molecular link between pulmonary carcinoids and
LCNEC that warrants further investigation.
Methods
Sample collection. All new specimens were collected from surgically resected
tumours, applying local regulations and rules at the collecting site, and including
patient consent for molecular analyses as well as collection of de-identiﬁed data,
with approval of the IARC Ethics Committee. These samples underwent an
independent pathological review. For the typical carcinoids and LCNEC, on which
methylation analyses were performed, the DNA came from the samples included in
already published studies4,11–14,35, for which the pathological review had already
been done.
Clinical data. Collected clinical data included age (in years), sex (male or female),
smoking status (never smoker, former smoker, passive smoker, and current smo-
ker), Union for International Cancer Control/American Joint Committee on
Cancer stage, professional exposure, and survival (calculated in months from
surgery to last day of follow-up or death). These data were merged with that from
Fernandez-Cuesta et al.11, George et al.12, and George et al.14. In order to improve
the power of the statistical analyses, we regrouped some levels of variables that had
few samples. Age was discretized into three categories ((15, 40], (40, 60], and (60,
90] years), Union for International Cancer Control stages were regrouped into four
categories (I, II, III, IV), and smoking status was regrouped into two categories
(non-smoker, that includes never smokers and passive smokers, and smoker, that
includes current and former smokers). In addition, one patient (S02236) that was
originally classiﬁed as male was switched to female based on its concordant whole-
exome, transcriptome, and methylome data; and one patient (LNEN028) for whom
no sex information was available was classiﬁed as male based on its methylation
data (Supplementary Fig. 28; see details of the methods used in the DNA
sequencing, expression, and methylation sections of the methods), because we had
no other data type for this sample. Note that two SCLC samples from George
et al.14 displayed Y chromosome expression patterns discordant with their clinical
data (S02249 and S02293; Supplementary Fig. 28B), but because we did not per-
form any analysis of SCLC samples that used sex information, this did not have any
impact on our analyses. See Supplementary Data 1 for the clinical data associated
with the samples.
We assessed the associations between clinical variables—a batch variable
(sample provider), the main variable of interest (histopathological type), and
important biological covariables (sex, age, smoking status, and tumour stage)—
using Fisher’s exact test, adjusting the p-values for multiple testing. Using samples
from all histopathological types (typical and atypical carcinoids, LCNEC, and
SCLC), we found that the sample provider was signiﬁcantly associated with the
histopathological type (Supplementary Fig. 29A). Indeed, the 20 carcinoids from
one of the providers (provider 1) are all atypical carcinoids. Nevertheless, because
there are also seven atypical carcinoids from a second provider and ﬁve from a
third one, variables provider and histopathological type are not completely
confounded and we could check for batch effects in the following molecular
analysis by making sure that the molecular proﬁles of atypical carcinoids from
provider 1 overlap with that from the two other providers. The histopathological
type was signiﬁcantly associated with all other variables (Supplementary Fig. 29A,
B, and C).
Pathological review. Some of the samples included in this manuscript had already
undergone a Central Pathological Review in the context of other published studies,
so we used the classiﬁcations from the supplementary tables of the corresponding
manuscripts4,11,12,14,35. For the new ones, an H&E (hematoxylin and eosin) stain
from a representative FFPE block was collected for all tumours for pathological
review. All tumours were classiﬁed according to the 2015 WHO classiﬁcation by
three independent pathologists (E.B., B.A.A., and S.L.). An H&E stain was also
performed in order to assess the quality of the frozen material used for molecular
analyses and to conﬁrm that all frozen samples contained at least 70% of
tumour cells.
Immunohistochemistry. FFPE tissue sections (3 µm thick) from 20 atypical and
typical carcinoids were deparafﬁnized and stained with the Ventana DLL3 (SP347)
assay, UltraView Universal DAB Detection Kit (Ventana Medical Systems and
Ampliﬁcation Kit (Ventana Medical Systems—Roche) on Ventana ULTRA auto-
stainer (Ventana, Roche, Meylan, France), and with the CD1 rabbit monoclonal
antibody (cl EP3622) (Ventana). The positivity of DLL3 was deﬁned by the per-
centage of tumour cells exhibiting a cytoplasmic staining, whatever the intensity.
The positivity of CD1A was deﬁned by the percentage of the total surface of the
tumour exhibiting a membrane staining with 1 corresponding to less than 1%, 2 to
a percentage between 1 and 5%, and 3 to greater than 5%. Results are presented
in Supplementary Data 9 and representative slides are shown in Fig. 4c.
Statistical analyses. All tests involving multiple comparisons were adjusted using
the Benjamini–Hochberg procedure controlling the false discovery rate46 using the
p.adjust R function (stats package version 3.4.4). All tests were two-sided. Also, a
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summary of the statistics associated with survival analyses is provided in Supple-
mentary Data 14.
Survival analysis. We performed survival analysis using Cox’s proportional
hazard model; we assessed the signiﬁcance of the hazard ratio between the refer-
ence and the other levels using Wald tests, and assessed the global signiﬁcance of
the model using the logrank test statistic (R package survival v. 2.41-3).
Kaplan–Meier and forest plots were drawn using R package survminer (v. 0.4.2).
Note that three LCNEC samples from George et al.14 had missing survival censor
information and were thus excluded from the analysis (samples S01580, S01581,
and S01586).
DNA extraction. Samples included were extracted using the Gentra Puregene
tissue kit 4g (Qiagen, Hilden, Germany), following the manufacturer's instructions.
All DNA samples were quantiﬁed by the ﬂuorometric method (Quant-iT Pico-
Green dsDNA Assay, Life Technologies, CA, USA), and assessed for purity by
NanoDrop (Thermo Scientiﬁc, MA, USA) 260/280 and 260/230 ratio measure-
ments. DNA integrity of Fresh Frozen samples was checked by electrophoresis in a
1.3% agarose gel.
RNA extraction. Samples included were extracted using the Allprep DNA/RNA
extraction kit (Qiagen, Hilden, Germany), following manufacturer's instructions.
All RNA samples were treated with DNAse I for 15 min at 30 °C. RNA integrity of
frozen samples was checked with Agilent 2100 Electrophoresis Bioanalyser system
(Agilent Biotechnologies, Santa Clara, CA95051, United States) using RNA 6000
Nano Kit (Agilent Biotechnologies).
Whole-genome sequencing (WGS). Whole-genome sequencing was performed
on three fresh frozen pulmonary carcinoids and matched-blood samples by the
Centre National de Recherche en Génomique Humaine (CNRGH, Institut de
Biologie François Jacob, CEA, Evry, France). After a complete quality control,
genomic DNA (1 µg) has been used to prepare a library for whole-genome
sequencing, using the Illumina TruSeq DNA PCR-Free Library Preparation Kit
(Illumina Inc., CA, USA), according to the manufacturer's instructions. After
normalisation and quality control, qualiﬁed libraries have been sequenced on a
HiSeqX5 platform from Illumina (Illumina Inc., CA, USA), as paired-end 150 bp
reads. One lane of HiSeqX5 ﬂow cell has been produced for each sample, in order
to reach an average sequencing depth of 30x for each sample. Sequence quality
parameters have been assessed throughout the sequencing run and standard
bioinformatics analysis of sequencing data was based on the Illumina pipeline to
generate fatsq ﬁles for each sample.
Whole-exome sequencing (WES). Whole-exome sequencing was performed on
16 fresh frozen atypical carcinoids in the Cologne Centre for Genomics. Exomes
were prepared by fragmenting 1 μg of DNA using sonication technology (Bior-
uptor, Diagenode, Liège, Belgium) followed by end repair and adapter ligation
including incorporation of Illumina TruSeq index barcodes on a Biomek FX
laboratory automation workstation from Beckman Coulter (Beckman Coulter,
Brea, CA, USA). After size selection and quantiﬁcation, pools of ﬁve libraries each
were subjected to enrichment using the SeqCap EZ v2 Library kit from NimbleGen
(44Mb). After validation (2200 TapeStation; Agilent Technologies, CA, USA), the
pools were quantiﬁed using the KAPA Library Quantiﬁcation kit (Peqlab, Erlan-
gen, Germany) and the 7900HT Sequence Detection System (Applied Biosystems,
Waltham, MA, USA), and subsequently sequenced on an Illumina HiSeq
2000 sequencing instrument using a paired-end 2 × 100 bp protocol and an allo-
cation of one pool with 5 exomes/lane. The expected average coverage was
approximately 120x after removal of duplicates (11 GB).
Targeted sequencing. Targeted sequencing was performed on the same 16 fresh
frozen atypical carcinoids and 13 matched-normal tissue for the samples with
enough DNA. Three sets of primers covering 1331 amplicons of 150–200 bp were
designed with the QIAGEN GeneRead DNAseq custom V2 Builder tool on
GRCh37 (gencode version 19). Target enrichment was performed using the
GeneRead DNAseq Panel PCR Kit V2 (QIAGEN) following a validated in-house
protocol (IARC). The multiplex PCR was performed with six separated primers
pools [(1) 1 pool covering 786 amplicons, (2) 4 pools covering 498 amplicons, and
(3) 1 pool covering 47 amplicons]. Per pool, 20 ng (1) or 10 ng (2 and 3) of DNA
were dispensed and air-dried (only 2 and 3). Subsequently 11 µL (1) or 5 µL (2 and
3) of the PCR mix were added [containing 5.5 µL (1) or 2.5 µL (2 and 3) Primer
mix pool (2x), 2.2 µL (1) or 1 µL (2 and 3) PCR Buffer (5x), 0.73 µL (1) or 0.34 µL
(2 and 3) HotStar Taq DNA Polymerase (6 U/µL) and 0.57 µL (1) or 1.16 µL (2
and 3) H2O] and the DNA were ampliﬁed in a 96-well-plate as following: 15 min at
95 °C; 25 (1), 21 (2), or 23 (3) cycles of 15 s at 95 °C and 4min at 60 °C; and 10 min
at 72 °C. For each sample, ampliﬁed PCR products were pooled together, puriﬁed
using 1.8x volume of SeraPure magnetic beads (prepared in-house following
protocol developed by Faircloth & Glenn, Ecol. And Evol. Biology, Univ. of
California, Los Angeles) (1) or NucleoMag® NGS Clean-up from Macherey-Nagel
(2 and 3) and quantiﬁed by Qubit DNA high-sensitivity assay kit (Invitrogen
Corporation). One-hundred nanograms of puriﬁed PCR product (6 µL) were used
for the library preparation with the NEBNext Fast DNA Library Prep Set (New
England BioLabs) following an in-house validated protocol (IARC). End repair was
performed [1.5 µL of NEBNext End Repair Reaction Buffer, 0.75 µL of NEBNext
End Repair Enzyme Mix, and 6.75 µL of H2O] followed by ligation to speciﬁc
adapters and in-house prepared individual barcodes (Euroﬁns MWG Operon,
Germany) [4.35 µL of H2O, 2.5 µL of T4 DNA Ligase Buffer for Ion Torrent, 0.7 µL
of Ion P1 adaptor (double-stranded), 0.25 µL of Bst 2.0 WarmStart DNA Poly-
merase, 1.5 µL of T4 DNA ligase, and 0.7 µL of in-house barcodes]. Bead pur-
iﬁcation of 1.8x was applied to clean libraries and 100 ng of adaptator ligated DNA
were ampliﬁed with 15 µL of Master Mix Ampliﬁcation [containing 1 µL of Pri-
mers, 12.5 µL of NEBNext High-Fidelity 2x PCR Master Mix, and 1.5 µL of H2O].
Pooling of libraries was performed equimolarly and loaded on a 2% agarose gel for
electrophoresis (220 V, 40 min). Using the GeneClean™ Turbo kit (MP Biomedicals,
USA) pooled DNA libraries were recovered from selected fragments of 200–300 bp
in length. Libraries quality and quantity were assessed using Agilent High Sensi-
tivity DNA kit on the Agilent 2100 Bioanalyzer on-chip electrophoreses (Agilent
Technologies). Sequencing of the libraries was performed on the Ion TorrentTM
Proton Sequencer (Life Technologies Corp) aiming for deep coverage (> 250x),
using the Ion PITM Hi-QTTM OT2 200 Kit and the Ion PITM Hi-QTM Sequencing
200 Kit with the Ion PITM Chip Kit v3 following the manufacturer’s protocols.
DNA data processing. WGS and WES reads mapping on reference genome
GRCh37 (gencode version 19) were performed using our in-house workﬂow
(https://github.com/IARCbioinfo/alignment-nf, revision number 9092214665).
This workﬂow is based on the nextﬂow domain-speciﬁc language47 and consists of
three steps: reads mapping (software bwa version 0.7.12-r1044)48, duplicate
marking (software samblaster, version 0.1.22)49, and reads sorting (software
sambamba, version 0.5.9)50. Reads mapping for the targeted sequencing data was
performed using the Torrent Suite software version 4.4.2 on reference genome
hg19. Local realignment around indels was then performed for both using software
ABRA (version 0.97bLE)51 on the regions from the bed ﬁles provided by Agilent
(SeqCap_EZ_Exome_v2_probe-covered.bed) and QIAGEN, respectively, for the
WES and targeted sequencing data. Consistency between sex reported in the
clinical data and WES data was assessed by computing the total coverage on X and
Y chromosomes (Supplementary Fig. 28A).
Variant calling and ﬁltering on DNA.WES data: We re-performed variant calling
for all typical and atypical carcinoid WES, including already published data, in
order to remove the possible cofounding effect of variant calling in the subsequent
molecular characterisation of carcinoids. Software Needlestack v1.1 (https://github.
com/IARCbioinfo/needlestack)52 was used to call variants. Needlestack is an ultra-
sensitive multi-sample variant caller that uses the joint information from multiple
samples to disentangle true variants from sequencing errors. We performed two
separate multi-sample variant callings to avoid technical batch effects: (1) The 16
WES atypical carcinoids newly sequenced in this study were analysed together with
64 additional WES samples sequenced using the same protocol from another study
in order to increase the accuracy of Needlestack to estimate the sequencing error
rate; (2) The 15 WES LNET (ten typical and ﬁve atypical carcinoids) previously
analysed (Fernandez-Cuesta et al.)11 were reanalysed with their matched-normal.
For both variant callings, we used default software parameters except for the
minimum median coverage to consider a site for calling, the minimum mapping
quality, and the SNV and INDEL strand bias13 threshold (they were set to 20, 13, 4,
and 10, respectively). Annotation of resulting variant calling format (VCF) ﬁles was
then performed with ANNOVAR (2018Aprl16)53 using the PopFreqAll (maximum
frequency over all populations in ESP6500, 1000G, and ExAC germline databases),
COSMIC v84, MCAP, REVEL, SIFT, and Polyphen (dbnsfp30a) databases.
We performed the same variant ﬁltering after each of the two variant callings,
based on several stringent criteria. First, we only retained variants that have never
been observed in germline databases or present at low frequency (≤ 0.001) but
already reported as somatic in the COSMIC database. Second, we only retained
variants that were in coding regions and that had an impact on expressed proteins:
we ﬁltered out silent, non-damaging single nucleotide variants (based on MCAP,
REVEL, SIFT, or Polyphen2 databases) and variants present in non-expressed
genes (mean and median FPKM < 0.1 over all carcinoid tumours). Additionally, for
calling (2), we re-assessed the somatic status of variants reported by Needlestack in
light of possible contamination errors. Indeed, Needlestack is a very sensitive caller
and will sometimes detect low allelic fraction variants in normal tissue that actually
come from contamination by tumour cells. In such cases the variant is found in
both matched samples and is reported as germline, but we still considered a variant
as somatic if its allelic fraction in the normal tissue was at least ﬁve times lower
than the allelic fraction observed in the tumour.
Targeted sequencing data: Software Needlestack was also used to call variants on
targeted sequencing data from 16 atypical carcinoids and their matched-normal
tissue. We performed the calling with default parameters except for the phred-
scaled q-value and minimum median coverage to consider a site (20 and 10,
respectively). These parameters were decreased compared to WES variants calling
because we wanted a larger sensitivity in the validation set than in the discovery set.
The annotation procedure was the same as for WES data. No other ﬁlters
were used.
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Validation: For both previously published data and data generated in this study,
we only report somatic mutations that were validated using a different technique:
targeted sequencing, RNA sequencing (see below for variant calling in RNA-seq
data), or Sanger sequencing. Results are presented Supplementary Data 4.
Structural variant calling. Somatic copy number variations (CNVs) were called
from WGS data using an in-house pipeline (software WGinR, available at https://
github.com/aviari/wginr) that consists of three main steps. First, the dependency
between GC content and raw read count is modelled using a generalised additive
smoothing model with two nested windows in order to catch short and long
distance dependencies. The model is computed on a subset of human genome
mappable regions deﬁned by a narrow band around the mode of binned raw counts
distribution. This limits the incorporation of true biological signal (losses and
gains) by selecting only regions with (supposedly) the same ploidy. In a second
step, we collect heterozygous positions in the matched-normal sample and GC-
corrected read counts (RC) and alleles frequencies (AF) at these positions are used
to estimate the mean tumour ploidy and its contamination by normal tissue. This
ploidy model is then used to infer the theoretical absolute copy number levels in
the tumour sample. In the third step, a simultaneous segmentation of RC and AF
signals (computed on all mappable regions) is performed using a bivariate Hidden
Markov Model to generate an absolute copy number and a genotype estimate for
each segment.
Somatic structural variants (SV) were identiﬁed using an in-house tool
(crisscross, available at https://github.com/anso-sertier/crisscross) that uses WGS
data and two complementary signals from the read alignments: (a) discordant pair
mapping (wrong read orientation or incorrect insert-size) and (b) soft-clipping
(unmapped ﬁrst or last bases of reads) that allows resolving SV breakpoints at the
base pair resolution. A cluster of discordant pairs and one or two clusters of soft-
clipped reads deﬁned an SV candidate: the discordant pairs cluster deﬁned two
associated regions, possibly on different chromosomes and the soft-clipped reads
cluster(s), located in these regions, pinpointed the potential SV breakpoint
positions. We further checked that the soft-clipped bases at each SV breakpoint
were correctly aligned in the neighbourhood of the associated region. SV events
were then classiﬁed as germline or somatic depending on their presence in the
matched-normal sample. Results are presented as Supplementary Data 8 and one
sample is highlighted in Fig. 3c.
Gene-set enrichment analysis of somatic mutations. Gene-set enrichment for
somatic mutations was assessed independently for each set of Hallmark of cancer
genes18 using Fisher’s exact test. We built the contingency tables used as input of
the test taking into account genes with multiple mutations and used the ﬁsher.test
R function (stats package version 3.4.4). We also included validated mutations (we
removed silent and intron/exon mutations) reported in SCLC13. In each group the
p-values given by Fisher’s exact test performed for all Hallmarks were adjusted for
multiple testing. Supplementary Data 5 lists the altered hallmarks, including the
mutated genes and the associated q-value for each group, as well as the mutated
genes for each hallmarks present in each supra-carcinoid, cluster LNET, LCNEC,
and SCLC samples.
We performed several robustness analyses to assess the validity of our results, in
particular with regards to outlier samples/genes that would have a high leverage on
the statistical results, i.e., that would alone drive the signiﬁcance of a particular
hallmark. First, we assessed the leverage of each individual sample using a jackknife
procedure (i.e., for each sample, we performed the GSE test after removing this
sample). Second, we assessed the leverage of each gene using a jackknife procedure
(i.e., for each gene, we performed the GSE test without this gene). We observed that
when we removed sample LNEN010 from the cluster LNET B, the sustaining
proliferative signalling hallmark enrichment became non-signiﬁcant at the 0.05
false discovery rate threshold, but was still signiﬁcant at the 10% threshold (q-value
= 0.075; Supplementary Data 3). Similarly, we observed that for several SCLC
samples, once the sample was removed, the deregulating cellular energetics and
inducing angiogenesis hallmarks became signiﬁcant at the 0.05 false discovery rate
threshold (Supplementary Data 5). For supra-carcinoids samples, we performed
GSE for each sample individually. The code used for the gene set enrichment
analyses on somatic mutations (Hallmarks_of_cancer_GSEA.R) is available in the
Supplementary Software ﬁle 1 and the associated results are reported in
Supplementary Data 5.
RNA sequencing. RNA sequencing was performed on 20 fresh frozen atypical
carcinoids in the Cologne Centre for Genomics. Libraries were prepared using the
Illumina® TruSeq® RNA sample preparation Kit. Library preparation started with
1 µg total RNA. After poly-A selection (using poly-T oligo-attached magnetic
beads), mRNA was puriﬁed and fragmented using divalent cations under elevated
temperature. The RNA fragments underwent reverse transcription using random
primers. This is followed by second strand complementary DNA (cDNA) synthesis
with DNA Polymerase I and RNase H. After end repair and A-tailing, indexing
adapters were ligated. The products were then puriﬁed and ampliﬁed (14 PCR
cycles) to create the ﬁnal cDNA libraries. After library validation and quantiﬁcation
(Agilent 2100 Bioanalyzer), equimolar amounts of library were pooled. The pool
was quantiﬁed by using the Peqlab KAPA Library Quantiﬁcation Kit and the
Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced
by using an Illumina TruSeq PE Cluster Kit v3 and an Illumina TruSeq SBS Kit v3-
HS on an Illumina HiSeq 2000 sequencer with a paired-end (101x7x101 cycles)
protocol.
RNA data processing. The 210 raw reads ﬁles (89 carcinoids, 69 LCNEC, 52
SCLC) were processed in three steps using the RNA-seq processing workﬂow based
on the nextﬂow language47 and accessible at https://github.com/IARCbioinfo/
RNAseq-nf (revision da7240d). (i) Reads were scanned for a part of Illumina’s
13 bp adapter sequence ′AGATCGGAAGAGC′ at the 3′ end using Trim Galore
v0.4.2 with default parameters. (ii) Reads were mapped to reference genome
GRCh37 (gencode version 19) using software STAR (v2.5.2b)54 with recommended
parameters55. (iii) For each sample, a raw read count table with gene-level quan-
tiﬁcation for each gene of the comprehensive gencode gene annotation ﬁle (release
19, containing 57,822 genes) was generated using script htseq-count from software
htseq (v0.8.0)56. Gene fragments per kilobase million (FPKM) of all genes from the
gencode gene annotation ﬁle were computed using software StringTie (v1.3.3b)57 in
single pass mode (no new transcript discovery), using the protocols from Pertea
et al.57 (nextﬂow pipeline accessible at https://github.com/IARCbioinfo/RNAseq-
transcript-nf; revision c5d114e42d).
Quality control of the samples was performed at each step. Software FastQC
(v. 0.11.5; https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to
check raw reads quality, software RSeQC (v. 2.6.4) was used to check alignment
quality (number of mapped reads, proportion of uniquely mapped reads). Software
MultiQC (v. 0.9)58 was used to aggregate the QC results across samples.
Concordance between sex reported in the clinical data and sex chromosome gene
expression patterns was performed by comparing the sum of variance-stabilised
read counts (vst function from R package DESeq2) of each sample on the X and Y
chromosomes (Supplementary Fig. 28B).
Variant calling on RNA. Software Needlestack was also used to call variants on the
20 RNA sequencing data for WES variant validation. Default parameters were used,
except for the phred-scaled q-value, minimum median coverage to consider a site,
and minimum mapping quality (20, 10, and 13, respectively). The annotation
procedure was the same as for WES data.
Fusion transcript detection. RNA-seq data was processed as previously
described11,13 to detect chimeric transcripts. In brief, paired-end RNA-seq reads
were mapped to the human reference genome (NCBI37/hg19) using GSNAP.
Potential chimeric fusion transcripts were identiﬁed using software TRUP59 by
discordant read pairs and by individual reads mapping to distinct chromosomal
locations. The sequence context of rearranged transcripts was reconstructed
around the identiﬁed breakpoint and the assembled fusion transcript was then
aligned to the human reference genome to determine the genes involved in the
fusion. All interesting fusion-transcript were validated by Sanger sequencing. The
code used for the fusion transcript detection is available on https://github.com/
ruping/TRUP. All the associated results are presented Supplementary Data 7, and
selected genes are highlighted in Fig. 3b.
Unsupervised analyses of expression data. The raw read counts of 57,822 genes
from the 210 samples were normalised using the variance stabilisation transform
(vst function from R package DESeq2 v1.14.1)60; this transformation enables
comparisons between samples with different library sizes and different variances in
expression across genes. We removed genes from the sex-chromosomes in order to
reduce the inﬂuence of sex on the expression proﬁles, resulting in a matrix of gene
expression with 54,851 genes and 210 samples. We performed four analyses, with
different subsets of samples. (i) An analysis with all 210 samples (LNEN and
SCLC), (ii) an analysis with LNEN samples only (158 samples), (iii) an analysis
with LNET and SCLC samples only (139 samples), and (iv) an analysis with LNET
samples only (89 samples). For each analysis, the most variable genes (explaining
50% of the total variance in variance-stabilised read counts) were selected (6398,
6009, 6234, and 5490 genes, respectively, for i, ii, iii, and iv). Principal component
analysis (PCA) was then performed independently for each analysis (function dudi.
pca from R package ade4 v1.7-8)61. Results are presented in Supplementary Fig. 6;
see the Multi-omic integration section of the methods for a comparison of the
results of the unsupervised analysis of expression data with that of the other 'omics.
We used the results from the PCA to detect outliers and batch effects in the
expression data set. We did not detect any outliers in any of the analyses from
Supplementary Fig. 6. We further studied the association between expression data,
batch (sample provider), and ﬁve clinical variables of interest (histopathological
type, age, sex, smoking status, and stage) using a PCA regression analysis. For each
principal component, we ﬁtted separate linear models with each of the six
covariables of interest (provider plus the ﬁve clinical variables) and adjusted the
resulting p-values for multiple testing. Results highlighted an association between
principal component 2 and provider, histopathological type, and sex, and an
association between principal components 4 and 5 and stage (Supplementary
Fig. 30A). The fact that both histopathology and sample provider are jointly
signiﬁcantly associated with PC2 is expected given their non-independence
(Supplementary Fig. 29A, B). In order to assess whether there was a batch effect
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explaining the variation on PC2, we investigated the range of samples from each
provider on PC2 (Supplementary Fig. 30B). We can see that samples from Provider
1 and provider 2 span a similar range on PC2 (from values less than –20 to values
greater than 40). Restricting the analysis to atypical carcinoids, we can further see
that AC samples from provider 2 have a range included in that of provider 1, which
is expected given their differing sample sizes (ﬁve from provider 2 compared to 20
from provider 1). Overall, this shows that samples from the two providers have
similar proﬁles and can be combined. In addition, we found that the samples that
were independently sequenced in a previous study11 and in this study (samples
S00716_A and S00716_B, respectively) were spatially close in the PCA (technical
replicates highlighted in Supplementary Fig. 30B).
Supervised analysis of expression data. We performed three distinct differential
expression (DE) analyses. (i) A comparison between histopathological types; (ii) A
comparison between pulmonary carcinoid (LNET) clusters A1, A2, and B (see
Fig. 5a and the Multi-omic integration method section); (iii) a comparison between
lung neuroendocrine neoplasm (LNEN) clusters Carcinoid A, Carcinoid B, and
LCNEC (see the Multi-omic integration method section).
For each differential expression (DE) analysis, among the 57,822 genes from the
raw read count tables, genes that were expressed in less than 2 samples were
removed from the analysis, using a threshold of 1 fragment per million reads
aligned. We also removed samples with missing data in the variables of interest
(either histopathological types, LNET clusters, or LNEN clusters) or in any of the
clinical covariables included in the statistical model (sex and age). This resulted in
excluding two samples with missing age data from the three analyses (samples
S01093, S02236), and further excluding three samples with no clear
histopathological type (classiﬁed as carcinoids in Supplementary Data 1) from
analysis (i) (samples S00076, S02126, S02154). For each analysis, we then identiﬁed
DE genes from the raw read counts using R package DESeq2 (v. 1.21.5)60. For each
analysis, we ﬁtted a model with the variable of interest (type, LNET cluster, or
LNEN cluster) and using sex (two levels: male and female), and age (three levels:
(16, 40], (40, 60], (60, 90]) as covariables. We then extracted DE genes between
each pair of groups, and adjusted the p-values for multiple testing. In order to select
the genes that have the largest biological effect, we tested the null hypothesis that
the two focal groups had less than 2 absolute log2-fold changes differences. For
each analysis, we deﬁne the core genes of a focal group as the set of genes that are
DE in all pairwise comparisons between the focal group and other groups; they
correspond to genes, which expression level is speciﬁc to the focal group. For
example, given three groups—A, B, and C—to ﬁnd core genes, which expression
levels uniquely deﬁne A compared to both B and C, we select DE genes that
differentiate A from B (A vs. B), DE genes that differentiate A from C (A vs. C) and
take the intersection of these gene sets [(A vs. B)∩(A vs. C)]. The code used for the
DE analyses (RNAseq_supervised.R) is available at https://github.com/
IARCbioinfo/RNAseq_analysis_scripts. Results of analysis (i) are reported in
Supplementary Data 15 and Supplementary Fig. 31; results of analysis (ii) are
reported in Supplementary Data 10 and Fig. 5a; results of analysis (iii) are reported
in Supplementary Data 12. See section Multi-omics integration for comparisons
between the analyses based on histopathological types [analysis (i)] from all ‘omics
perspectives.
Note that an alternative method for ﬁnding DE genes would be to compare a
focal group to all the other samples together. For example, comparing group A to
both groups B and C simultaneously [denoted A vs. (B and C) or A vs. the rest].
Note that this would ﬁnd genes that are DE between A and the average level of
expression of B and C, and thus this alternative method would have the unwanted
behaviour of including the genes that are strongly DE in the comparison of A vs. B,
but with similar expression levels in A and C. In order to compare the methods we
used to detect core genes with this alternative method, we performed an analysis
similar to analysis (ii) but comparing a focal group to all the other samples
simultaneously (A vs. the rest). The comparison between our method and the
alternative one is presented in Supplementary Fig. 21 and shows that our analysis
provides conservative results compared to testing the focal group vs. the rest.
Indeed, core DE genes reported are almost exclusively a subset of the genes found
when comparing the focal group vs. the rest.
Immune contexture deconvolution from expression data. We quantiﬁed the
proportion of cells that belong to each of ten immune cell types (B cells, macro-
phages M1, macrophages M2, monocytes, neutrophils, NK cells, CD4+ T cells,
CD8+ T cells, CD4+ regulatory T cells, and dendritic cells) from the RNA-seq
data using software quanTIseq (downloaded 23 March 2018)62. quanTIseq uses a
rigorous RNA-seq processing pipeline to quantify the gene expression of each
sample, and performs supervised expression deconvolution in a set of genes
identiﬁed as informative on immune cell types, using the least squares with
equality/inequality constrains (LSEI) algorithm with a reference data set containing
expected expression levels for the ten immune cell types. Importantly, quanTIseq
also provides estimates of the total proportion of cells in the bulk sequencing that
do and do not belong to immune cells.
We tested whether immune composition differed between histopathological
types, LNET clusters, LNEN clusters, and supra-carcinoids using linear
permutation tests (R package lmperm, v. 2.1.0). Permutations tests are exact
statistical tests that do not rely on approximations and assumptions regarding the
data distribution, and are thus well-ﬁtted to test whether a few samples come from
the same distribution as a larger group of samples. As such, they were well-ﬁtted to
handle the tests involving supra-carcinoids, for which only three samples had
RNA-seq data. For each of the three analyses (histopathology, LNET clusters, and
LNEN clusters), and for each pair of groups, we ﬁtted one model per immune cell
type, with the proportion of this cell type in each sample as explained variable and
the cluster membership as explanatory variable. We adjusted the p-values for
multiple testing. The code used for these three analyses is available on https://icbi.i-
med.ac.at/software/quantiseq/doc/index.html and the associated results are
presented Figs. 2f, 4b, and Supplementary Figs. 15, 19, and 32.
EPIC 850k methylation array. Epigenome analysis was performed on 33 typical
carcinoids, 23 atypical carcinoids, and 20 LCNEC, plus 19 technical replicates.
Epigenomic studies were performed at the International Agency for Research on
Cancer (IARC) with the Inﬁnium EPIC DNA methylation beadchip platform
(Illumina) used for the interrogation of over 850,000 CpG sites (dinucleotides that
are the main target for methylation). Each chip encompasses eight samples, so 12
chips were needed for the 95 samples. We used stratiﬁed randomisation to mitigate
the batch effects, ensuring that the three histopathological types were present on
every chip, while also controlling for potential confounders (the sample provider,
sex, smoking status, and age of the patient); replicates were placed on
different chips.
For each sample, 600 ng of puriﬁed DNA were bisulﬁte converted using the EZ-
96 DNA Methylation-GoldTM kit (Zymo Research Corp., CA, USA) following the
manufacturer's recommendations for Inﬁnium assays. Three replicates included
half the amount (300 ng). Then, 200 ng of bisulﬁte-converted DNA was used for
hybridisation on Inﬁnium Methylation EPIC beadarrays, following the
manufacturer’s protocol (Illumina Inc.). This array shares the Inﬁnium HD
chemistry (Illumina Inc.) and a similar laboratory protocol used to interrogate the
cytosine markers with HumanMethylation450 beadchip. Chips were scanned using
Illumina iScan to produce two-colour raw data ﬁles (IDAT format).
Methylation data processing. The resulting IDAT raw data ﬁles were pre-
processed using R packages minﬁ (v. 1.24.0)63 and ENmix (v. 1.14.0)64. We ﬁrst
removed unwanted technical variation in-between arrays using functional nor-
malisation of the raw two-colour intensities, and computed the β-values for the
866,238 probes and 96 samples. Then, we ﬁltered four types of probes that could
confound the analyses. (i) We removed probes on the X and Y chromosomes,
because we were interested in variation between tumours and treated sex as a
confounder. (ii) We removed known cross-reactive probes—i.e., probes that co-
hybridise to other chromosomes and thus cannot be reliably investigated. (iii) We
removed probes that had failed in at least one sample, using a detection p-value
threshold of 0.01, where p-values were computed with the detection P function
from R package minﬁ, that compares the total signal (methylated+ unmethylated)
at each probe with the background signal level from non-negative control probes.
(iv) We removed probes associated with common SNPs—that reﬂect underlying
polymorphisms rather than methylation proﬁles—using a threshold minor allele
frequency of 5% in database dbSNP build 137 (function dropLociWithSnps from
minﬁ). (v) We removed probes putatively associated with rare SNPs by detecting
and removing probes with multimodal β-value distributions (function nmode.mc
from R package ENmix). Next, we removed duplicated samples, randomly
choosing one sample per pair so as to minimise potential discrepancies, and we
removed one sample that came from a metastatic tumour rather than a primary
tumour. The ﬁnal data set contained the β-values of 767,781 CpGs for 76 samples.
We performed quality controls of the raw data. Two-colour intensity data of
internal control probes were inspected to check the quality of successive sample
preparation steps (bisulﬁte conversion, hybridisation). We did not ﬁnd outliers
when comparing the methylated/unmethylated channel intensities of all samples,
nor did we ﬁnd samples with overall low detection p-values (the sample with the
lowest mean p-value had a value of 0.001). Concordance between the sex reported
in the clinical data and the methylation data was assessed using a predictor based
on the median total intensity on sex-chromosomes, with a cutoff of –2 log2
estimated copy number (function getSex from minﬁ). Consistently with the WES
and RNA-seq data, we found one sample with a mismatch between reported and
inferred sex (see results in Supplementary Fig. 28C). We investigated batch effects
at the raw data level using surrogate variable analysis. We used function ctrlsva
from package ENmix to compute a principal component analysis of the intensity
data from non-negative control probes. We retained the ﬁrst ten principal
components—hereafter referred to as surrogate variables—explaining >90% of the
variation in control probes intensity. The ten surrogate variables were included as
covariables in later supervised analyses to mitigate the impact of batch effects on
the results. We checked the association of surrogate variables with batch (chip,
position on the chip, and sample provider) and clinical variables (histopathological
type, age, sex, smoking status) using PCA regression analysis, ﬁtting separate linear
models to each surrogate variable with each of the seven covariables of interest and
adjusted the p-values for multiple testing. We show in Supplementary Fig. 33A that
surrogate variables 1, 2, 3, and 10 are signiﬁcantly associated with the chip (variable
Sentrix id) or position on the chip (variable Sentrix position), while surrogate
variables 4, 5, and 10 are signiﬁcantly associated with the sample provider. The
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code used to perform all the pre-processing procedure of these data is available at
https://github.com/IARCbioinfo/Methylation_analysis_scripts.
Unsupervised analysis of methylation data. The β-values of 767,781 CpGs for
76 samples were transformed into M-values to perform unsupervised analyses;
indeed, contrary to β-values, M-values theoretically range from −∞ to +∞ and are
considered normally distributed. We performed two analyses, with different subsets
of samples: (i) an analysis with all carcinoid and LCNEC samples (76 samples), and
(ii) an analysis with carcinoid samples only (56 samples). For each analysis, the
most variable CpGs (explaining 5% of the total variance in M-values) were selected
(8,483 and 7,693 CpGs, respectively, for (i) and (ii). PCA was then performed
independently for each analysis (function dudi.pca from R package ade4 v1.7-8)61.
Results are presented in Supplementary Fig. 7; see the Multi-omic integration
section of the methods for a comparison of the results of the unsupervised analysis
of methylation data with that of the other 'omics.
We used the results from the PCA to detect outliers and batch effects in the
methylation data set. We did not detect any outliers in any of the analyses from
Supplementary Fig. 7. We also performed a PCA regression analysis using the same
protocol as described in the data processing section above. Results highlighted no
association between any principal component and array batches (chip and position
in the chip; Supplementary Fig. 33A). Principal component 2 was associated with
the sample provider; further examination of the PCA (Supplementary Fig. 33B)
revealed that this effect was driven by the samples from provider 1, which have the
largest range of coordinates on PC2 (from < –30 to >100). Nevertheless, the fact
that their coordinates on PC2 overlap with that of samples from other providers,
and the fact that the vast majority of atypical carcinoid samples come from one
provider, suggest that the large range of values of provider 1 samples on PC2 is
driven by the biological variability of carcinoid methylation proﬁles. In addition,
note that samples that cluster with LCNEC are not solely from provider 1. We
assessed the impact of functional normalisation on batch effects by performing the
same analysis on the M-values of the 5% most variable CpGs obtained without
normalisation (Supplementary Fig. 33A). Compared to the PCA of the 5% most
variable CpGs with normalisation (Supplementary Fig. 33A), we ﬁnd that the chip
position (variable Sentrix position) is signiﬁcantly associated with PC10, and that
PC2 is not associated with histopathology. This suggests that the functional
normalisation reduced batch effects and revealed some of the biological variability
in methylation data.
The PCA is also informative about associations between methylation proﬁles
and clinical variables. We ﬁnd a signiﬁcant association between PC1,
histopathological type, age, and smoking status, with LCNEC, smokers, and larger
age classes located at higher PC1 coordinates (Supplementary Fig. 33A); these
associations are expected, given that the difference between LCNEC and carcinoids
is expected to be the main driver of variation in methylation, and given known the
aetiology of the diseases8. We ﬁnd an association between principal component 2,
histopathology, and sex, with male and atypical carcinoids having overall larger
PC2 coordinates. We ﬁnd associations of larger components, in particular PC3 and
age, and PC7 and 9, and sex.
Supervised analysis of methylation data. We detected differential methylation at
the probe level (DMP) in three independent analyses: (i) between histopathological
types (TC, AC, and LCNEC), (ii) between LNET clusters (clusters A1, A2, and B),
and (iii) between LNEN clusters (clusters A, B, and LCNEC).
To detect DMPs, for each analysis, linear models were ﬁrst ﬁtted independently for
each CpG to its M-values (function lmFit from R package limma version 3.34.9)65,
using the variable of interest (histopathology, LNET cluster, or LNEN cluster), in
addition to the sex, age group, and the ten surrogate variables as covariables. Then,
moderated t-tests were performed by empirical Bayes moderation of the standard
errors (function eBayes from package limma), and p-values were computed for each
CpG. Moderation enables to increase the statistical power of the test by increasing the
effective degrees of freedom of the statistics, while also reducing the false-positive rate
by protecting against hypervariable CpGs, and are thus favoured in array analyses.
The p-values were adjusted for multiple testing, and CpGs with a q-value <0.05 were
retained. The code used for the DMPs identiﬁcation (DMP.R) is available in the
Supplementary Software 1 and the associated results of analyses (i), (ii), and (iii)
are presented Supplementary Data 16, Supplementary Data 11, and 17, respectively.
See section Multi-omics integration for comparisons between the analyses based
on histopathological types [analysis (i)] from all ‘omics perspectives. Analysis (iii)
conﬁrmed most DMPs associated with DEGs reported in Fig. 5a for cluster B relative
to LNET clusters (TFF1, OTOP3, SLC35D3, APOBEC2) were also DMPs for cluster
B relative to LNEN clusters, showing that they harboured speciﬁc methylation levels
that made them different from the LCNEC cluster, as well as from other carcinoid
clusters.
Multi-omics integration. We performed an integrative analysis of the WES, WGS,
RNA-seq, and 850 K methylation array data, using the validated somatic mutations
(Supplementary Data 4), the variance-stabilised read counts, and the M-values,
respectively. The full data set consisted of 243 samples, but some analyses focused
on a subset of the data.
Unsupervised continuous multi-omic analyses. To perform continuous latent
factors identiﬁcation, we performed an integrative group factor analysis of the
expression and methylation data using software MOFA (R package MOFAtools
v. 0.99)15. MOFA identiﬁes latent factors (LF, i.e., continuous variables) that explain
most variation in the joint data sets. We did not include the somatic mutations in the
model because the low level of recurrence (only four recurrently mutated genes in
Supplementary Data 4) resulted in a sample by mutation matrix of much lower
dimension than the other ‘omics, which is known to bias the analyses15. Also, we did
not consider expression and methylation from the sex-chromosomes, because we were
interested in differences between tumours independently of the sex of the patient.
We performed four analyses, with different subsets of samples. (i) An analysis
with all 235 samples for which expression or methylation data was available (LNEN
and SCLC), (ii) an analysis with LNEN samples only (183 samples), (iii) an analysis
with LNET and SCLC samples only (163 samples), and (iv) an analysis with LNET
samples only (111 samples). For each analysis, the most variable genes for
expression (explaining 50% of the total variance) were selected (6398, 6009, 6234,
and 5490 genes, respectively, for i, ii, iii, and iv), and the most variable CpGs
(explaining 5% of the total variance) were selected (8483, 8483, 7693, and 7693
CpGs, respectively, for i, ii, iii, and iv). Note that these lists of genes and CpGs are
the same as the ones used to perform the unsupervised analyses of expression and
methylation data (see above sections). Also note that we did not have EPIC 850k
methylation array data for SCLC; MOFA was shown to handle missing data,
including samples with entire ‘omic techniques missing, by using the correlated
signals from several data sets (e.g., expression and methylation) to accurately
reconstruct latent factors. MOFA was performed independently for each analysis,
setting the number of latent factors to 5, because subsequent latent factors
explained <2% of the variance of both ‘omic data sets (function runMOFA from R
package MOFAtools v0.99.0). Because MOFA uses a heuristic algorithm, we
assessed the robustness of the results using 20 MOFA runs. We then computed the
correlations between each of the ﬁve ﬁrst-latent factors across each run, resulting in
a correlation matrix of 100 by 100 entries (Supplementary Figs. 2 and 17). We
found that the correlations across runs were very high (> 0.95 for >80% of runs) in
all analyses, suggesting that the results are robust. In addition, we found that
correlations between latent factors within runs were small (typically below 0.2),
which suggests that latent factors capture quasi-independent sources of variation in
the data sets. For each analysis, we selected the MOFA run that resulted in the best
convergence, based on the evidence lower bound statistic (ELBO). Results are
presented in Figs. 1a, 4a, and Supplementary Fig. 13. Interestingly, we ﬁnd that
MOFA latent factors 1 to 3 for analysis (i) (LNET, LCNEC, and SCLC) correspond
to MOFA LF2 to 4 for analysis (ii) (LNET and LCNEC), and to MOFA LF3 to 5 for
analysis (iv) (LNET alone); this suggests that each histopathological type introduces
an independent source of variation, resulting in a new LF. The code used for the
unsupervised continuous molecular analyses (integration_MOFA.R) is available on
https://github.com/IARCbioinfo/integration_analysis_scripts.
To perform comparisons with uni-omic unsupervised analyses, we compared the
results of MOFA with that of the unsupervised analysis of expression and
methylation data (Supplementary Fig. 3). To do so, we used the 51 LNEN samples
for which we had both expression and methylation data, and extracted their
coordinates in MOFA, expression PCA (see section unsupervised analysis of
expression data), and methylation PCA (see section unsupervised analysis of
methylation data). When using LNET and LCNEC samples (Supplementary
Fig. 3A), we found that MOFA LF1 is strongly correlated with expression PC1 and
methylation PC1 (|r| > 0.98; Supplementary Fig. 3D, E), and that expression PC1 and
methylation PC1 are strongly correlated between them (r= 0.97; Supplementary
Fig. 3C); LF2 was strongly correlated with expression PC3 (r= –0.86; Supplementary
Fig. 3P), and methylation PC2 (r= –0.98; Supplementary Fig. 3K), suggesting that
LF2 is more driven by methylation differences, but that it is nonetheless consistent
with a large proportion of expression variation. On the contrary, LF3 was more
strongly correlated with expression PC2 (r= 0.87; Supplementary Fig. 3J), suggesting
that PC3 is more driven by expression differences. All these observations are
consistent with the fact that the percentage of variance explained by LF2 and LF3 in
terms of expression and in terms of methylation are different: LF2 explains more
expression in methylation, while LF3 explains more variation in expression (Fig. 1a);
it is also coherent with the fact that clusters A1 and A2 are the most separated
clusters on expression PC2 (Supplementary Fig. 6B), while clusters A1 and B are the
most separated on methylation PC2 (Supplementary Fig. 7A). When using LNET
samples only (Supplementary Fig. 3B), we found that MOFA LF1 is strongly
correlated with expression PC2 and methylation PC1 (|r| > 0.86; Supplementary
Fig. 3M, H), and that expression PC2 and methylation PC1 are strongly correlated
between them (r= 0.72; Supplementary Fig. 3F); LF2 was strongly correlated with
expression PC1 (r= –0.88; Supplementary Fig. 3G), and methylation PC2 (r= 0.90;
Supplementary Fig. 3N), suggesting that LF2 is more driven by methylation
differences, but that it is nonetheless consistent with a large proportion of
expression variation. Again, all these observations are consistent with the fact that
the percentage of variance explained by LF1 and LF2 in terms of expression and
in terms of methylation are different (Fig. 4a); it is also coherent with the fact
that clusters A1 and A2 are the most separated clusters on expression PC1
(Supplementary Fig. 6D), while clusters A1 and B are the most separated on
methylation PC2 (Supplementary Fig. 7B).
To perform associations of latent factors with other variables, we used the
results from MOFA to detect outliers and batch effects in the data set. We did not
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detect any outliers in any of the analyses from Supplementary Fig. 13. We further
studied the associations between the ﬁrst 5 LFs, batch (sample provider), and ﬁve
clinical variables of interest (histopathological type, age, sex, smoking status, and
stage) using regression analysis. For each latent factor, we ﬁtted a linear model with
the six covariables of interest (provider plus the ﬁve clinical variables). Because of
the reported association between sex, age, and smoking status, we also included in
the model the interaction between sex and smoking status and between age and
smoking status; we adjusted the resulting p-values for multiple testing. Signiﬁcant
associations (q-value < 0.05) are highlighted in Figs. 1a and 4a.
We also tested the association between MOFA clusters and mutations using
regression analysis. We tested genes recurrently mutated in carcinoids, using a
threshold of three samples (following Argelaguet et al.)15; indeed, non-recurrent
genes are not informative about molecular groups. Only two genes were retained:
MEN1 and EIF1AX. We also included recurrently mutated genes reported in
LCNEC12. Results are highlighted in Fig. 4a. Similarly, we tested the association
between pathways highlighted in Supplementary Fig. 16 (Lysine
demethyltransferases, polycomb complex, SWI/SNF complex) and MOFA LF using
regression analysis, but did not ﬁnd any signiﬁcant association at a false discovery
rate threshold of 0.05.
Unsupervised discrete multi-omic analyses. We identiﬁed molecular clusters—
groups of samples with similar molecular proﬁles—from MOFA results. Following
Mo et al.66, given a speciﬁed number of clusters K, we used the K – 1 latent factors
that explained most of the variation to perform clustering; this choice of number of
latent factors in Mo et al.66 is said to be primarily motivated by “a general principle
for separating g clusters among the n datapoints, a rank-k approximation where
k ≤ g− 1 is sufﬁcient.” In addition, because the MOFA latent factors explaining the
most variance in gene expression and methylation are expected to capture more
biological signal compared to the ones explaining the least variance—expected to
represent more of the noise in the data set—we expect that using the ﬁrst K – 1
latent factors would provide more biologically meaningful clusters than using all
latent factors. In addition, following the procedure from Wilkerson and Hayes67,
we performed consensus clustering to detect robust molecular clusters. This pro-
cedure involved multiple replicate clusterings (K-means algorithm; R function
kmeans), each on latent factors from an independent MOFA run done on a sub-
sample (80%) of the data. Pairwise consensus values were deﬁned as the proportion
of runs in which two samples are clustered together and used as a similarity
measure, and used to perform a ﬁnal hierarchical clustering (median linkage
method). Consensus clustering results for K from 2 to 5, for LNET plus LCNEC
samples, and LNET samples alone, are presented in Supplementary Figs. 5 and 18,
respectively. In the case of LNET alone, because the optimal Dunn index, which
evaluates the quality of clustering as a ratio of within-cluster to between-cluster
distances, corresponded to K= 3 clusters (Supplementary Fig. 18C), we chose the
solution with three clusters. Nevertheless, note that the cluster memberships for K
= 4 and K= 5 are almost perfectly nested into that for K= 3 (e.g., samples from
the blue cluster for K= 3, Supplementary Fig. 18B are split between a blue and a
purple cluster for K= 4), so the solutions with three and four clusters are coherent.
Cluster memberships are highlighted in Fig. 4a. Similarly, in the case of LNET plus
LCNEC samples (LNEN), because the optimal Dunn index is reached when K= 3,
we chose that solution, but note that the cluster memberships for K > 3 are also
nested into that for K= 3, so all results are coherent across values of K.
In order to test whether using additional latent factors could increase the power
to detect molecular clusters, we performed a similar analysis but using all ﬁve latent
factors identiﬁed by MOFA. In order to provide more importance to the factors
most likely to capture the biological variation in the data, the multiple replicate
clusterings were performed using a weighted k-means algorithm, where variables
(here MOFA latent factors) are given weights corresponding to their proportion of
variance explained. More speciﬁcally, instead of minimising the within-cluster sum
of squares, the weighted within-cluster sum of squares is minimised. Results for
K= 3 clusters of LNET and LNEN samples are presented in Supplementary Fig. 8.
We can see that the alternative approach (weighted K-means on ﬁve latent factors)
leads to the exact same cluster membership as the original approach (K-means on
K – 1 latent factors), both for LNEN and LNET clusters. Indeed, among the latent
factors, only the ﬁrst 3 were associated with either the LNEN clusters (ANOVA
q= 4.09 × 10−84, 8.63 × 10−80, 0.66, 0.094, 0.24, respectively, for latent factors 1
through 5) or the LNET clusters (ANOVA q= 5.06 × 10−4, 5.99 × 10−47, 5.12 ×
10−46, 0.15, 0.052, respectively), which indicates that the ﬁrst three latent factors
captured the differences between clusters. The code used for the clustering analyses
(integration_unsupervised.R) is available at https://github.com/IARCbioinfo/
integration_analysis_scripts.
GSEA on multi-omic latent factors. We performed gene set enrichment analysis
(GSEA) on the latent factors identiﬁed by MOFA using the built-in function
FeatureSetEnrichmentAnalysis15. This tests for each latent factor whether the
distribution of the loadings of features (genes or CpGs) from a focal set are sig-
niﬁcantly different from the global distribution of loadings from features outside
the set. We performed the analysis using two reference databases of gene sets: GO
and KEGG. To retrieve the appropriate databases, for all genes from the muti-
omics integration analysis, we downloaded GO terms using R package biomaRt68,
and we retrieved KEGG pathways using R package KEGGgraph (v. 1.38.0)69.
Results are presented in Supplementary Data 6.
Expression and methylation correlation analysis. We performed correlation
tests in two analyses: (i) between LNET clusters (clusters A1, A2, and B), and (ii)
between LNEN clusters (clusters A, B, and LCNEC). We selected for each gene, the
set of CpGs in the region −2000 to +2000 from the transcription start site (TSS)
using function getnearestTSS from R package FDb.InﬁniumMethylation.hg19
version 2.2.0 based on the IlluminaHumanMethylationEPICanno.ilm10b2.hg19
annotation (get Annotation function from R package minﬁ version 1.24.0)63.
We performed correlation test analyses (function cor.test from R package stats
version 3.5.1) using the core genes lists (Supplementary Data 10 and 12) to ﬁnd
associations between expression and methylation data for each CpG, using
Pearson's correlation coefﬁcient. The p-values were adjusted for multiple testing. In
addition, we explored the correlation between expression and methylation data by
ﬁtting a linear model independently for each correlated CpG (function lm from R
package stats version 3.5.1). Finally, we calculated the interquartile distance of
β-values for each CpG. CpGs with a q-value < 0.05, r2 > 0.5 and an interquartile
distance greater than 0.25 were retained and, among these CpGs, only the one with
the smallest q-value has been represented in Supplementary Fig. 22. Results of
analyses (i) and (ii) are reported in Supplementary Data 10 and 12.
Survival analysis using penalised generalised linear model. We computed
a generalised linear model with elastic net regularisation (R package glmnet
v2.0-16)70 to select the genes associated with the survival of LNET samples. We
ﬁxed the elastic net mixing parameter α to 0.5 and used leave-one-out cross-
validation to determine the regularisation parameter λ (cv.glmnet function from
glmnet package). To be more stringent, the optimal regularisation parameter
chosen was the one associated with the most regularised model with cross-
validation error within one standard deviation of the minimum. In order to
identify the genes associated with the poor survival of the cluster Carcinoid B, we
included in the model only the expression of the core genes of this cluster deﬁned
in the MOFA considering only the LNET samples (see section Multi-omics inte-
gration). We used the normalised read counts, and centred and scaled them using
R package caret (v6.0-80). The genes with non-zero estimated coefﬁcients are listed
in Supplementary Data 13. For each non-coding gene, we determined the optimal
cutpoint of expression (normalised read counts) that best separates the survival
outcome into two groups using the surv_cutpoint function based on the maximally
selected rank statistics and available in the R package survminer (v0.4.3). The
minimal proportion of samples per group was set to 10%.
Supervised multi-omic analyses. We performed supervised learning in order to
classify typical and atypical carcinoids, and LCNEC based on the different 'omics
data available: expression and methylation data.
Classiﬁcation algorithm: Each classiﬁcation was performed using a random
forest algorithm (R package randomForest v4.6-14). Considering the restricted
number of samples, we performed a leave-one-out cross-validation. For each run,
to increase the training set size, minority classes were oversampled so that all
classes reach the same number of training samples. Note that for the sample with
technical replication of RNA-seq data (S00716_A and S00716_B), in order to avoid
model overﬁtting, the two replicates were never simultaneously included in the
training and test sets. Also in order to avoid overﬁtting, we performed
normalisation and independent feature ﬁltering within each fold, so that test
samples were excluded from this step. More speciﬁcally, for the expression data, the
features of the training set were ﬁrst normalised using the variance stabilisation
transformation (vst function from R package DESeq2 v1.22.2), then mean-centred
and scaled to unit variance. Then, the variance stabilising transformation learned
from the training set was applied to the test set using the dispersionFunction
function from the DESeq2 package, and centreing and scaling were performed
using the values learned from the training set. For the methylation data, the M
values were computed using the R package minﬁ (v1.28.3); the features of the
training set were mean-centred and scaled to unit variance, then the test sample
features were centred and scaled using the values learned from the training set. For
each fold of the leave-one out, the training set was used for the feature selection.
Based on the training set, we selected the most variable features, representing 50%
and 5% of the total variation in expression and methylation data, respectively. The
code used for the machine learning analyses (ML_functions.r) is available in the
Supplementary Software 1 and the associated results are reported in Supplementary
Data 1.
Deﬁning an Unclassiﬁed category: The random forest algorithm provides for
each predicted sample the class probabilities. We considered a sample as
unclassiﬁable (Unclassiﬁed category) if the ratio of the two highest probabilities
was below 1.5. In fact, this threshold allowed us to identify a category of samples
with intermediate molecular proﬁles, for which the algorithm assigns similar
probabilities to the two most probable classes. Because of the small sample size, this
parameter was chosen a priori and not tuned in order to avoid overﬁtting. In
Supplementary Fig. 10, we compared the classiﬁcation results when considering
three different thresholds: 1 (which corresponds to no ratio and results in few
unclassiﬁed samples, i.e., only discordant expression and methylation-based
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predictions, see Integration of expression and methylation data below), 1.5 (which
corresponds to the ratio reported in the main text), and 3 (which corresponds to a
very stringent ratio resulting in more unclassiﬁed samples). Except for the size of
the unclassiﬁed classes that depends on the ratio used, the confusion matrices for
the three ratios were qualitatively similar, with most LCNEC samples correctly
classiﬁed, a majority of typical correctly classiﬁed, and almost as many atypical
classiﬁed as typical and classiﬁed as atypical. In addition, the survival analyses of
the three models also led to similar conclusions, with atypical carcinoids classiﬁed
as atypical by the machine learning having a survival that is not statistically
signiﬁcantly different from that of LCNEC samples but that is lower from both that
of typical carcinoids predicted as typical carcinoids, and that of atypical predicted
as typical. However, in the case of the largest ratio, the small number of atypical
samples predicted in those categories did not enable the identiﬁcation of two
groups of atypical carcinoids with signiﬁcant different overall survival (p= 0.086).
Number of samples and features: To classify LCNEC against atypical and typical
carcinoids, 157 and 76 samples were considered using the expression and
methylation data, respectively. The number of features selected in each fold of the
leave-one-out are of the order of 6000 and 8000 for expression and methylation
features, respectively. For the analysis based on MKI67 only (Supplementary
Fig. 31C, left panel), the only feature considered was the expression of MKI67.
Integration of expression and methylation data: As the random forest algorithm
does not handle missing data directly, and because only 51 out of 182 LNEN
samples had both expression and methylation data available (Supplementary
Fig. 1), we performed random forest classiﬁcation on expression and methylation
separately, and merged the classiﬁcation results by combining the two sets of ML
predictions. Thus, the samples with both expression and methylation data were
associated with two predictions. When the two predictions were discordant we
applied the following rules: (i) if one prediction was Unclassiﬁed (see Deﬁning an
Unclassiﬁed category above) and the other a histopathological category, we chose
the histopathological category (ii) if the two predictions were different
histopathological categories, we chose the Unclassiﬁed category.
Note that ﬁtting independent random forest models on each data set separately
corresponds to maximising the number of samples (n) per model at the expense of
the number of features (p), because each model relies only on the number of
features in a single data set. An alternative approach is to maximise the number of
features (p) by combining both data sets, at the expense of the number of samples
n, because of the limited number of samples with both data types available. Indeed,
for ﬁxed n increasing p requires less parameters and leads to a higher statistical
power. Nevertheless, in our case, because of missing data, increasing p by using
both omics layers would drastically reduce n, restricting our sample set (n= 157
and n= 76 for expression and methylation, respectively) to the set of samples with
both layers (n= 51, including only a single supra-carcinoid). Given the existence of
very rare entities such as the supra-carcinoids, accurately capturing the diversity of
molecular proﬁles in the training set was our priority, and thus we chose to
maximise n. In addition, by maximising n, we hypothetically ensured that we
would also maximise the power of the subsequent analyses based on the ML results.
To conﬁrm this hypothesis, we performed the ML analyses on the restricted set of
samples, including both expression and methylation data in the same model and
compared the predictions of this model to the combined predictions based on
expression and methylation data separately. We found that the predictions
(confusion matrix in Supplementary Fig. 9) were similar, with 43/51 samples with
both data types predicted similarly in the two models. In addition, our main ﬁnding
—the existence of two groups of atypical samples, which tended to have a good and
bad prognosis (red and pink curves Fig. 1b)—still held, but that limited number of
samples impeded the statistical analyses. In fact, none of the Cox regression tests
were signiﬁcant even for the groups displaying the largest differences (e.g., ML-
predicted LCNEC vs. ML-predicted typical samples), and even when comparing
the histological types reported by the pathologists (bottom panel Supplementary
Fig. 9). This supports our hypothesis that maximising p at the expense of n leads to
a decrease in power in subsequent analyses due to a smaller sample size, and
comforts our initial choice.
As matrix factorisation methods such as MOFA and PCA remove correlations
between features by ﬁnding latent factors that summarise them, they could
presumably improve the performance of ML. Nevertheless, by providing low-
dimensional approximations of the data, such techniques induce a loss of
information, which could reduce the performance of the ML. To assess the balance
between these beneﬁcial and detrimental effects, we also performed ML using the
MOFA factors or the principal components of the PCA analysis, using factors or
components that explained at least 2% of the variance (ﬁve MOFA latent factors,
six expression PCs, and ﬁve methylation PCs, respectively). These analyses are
presented in Supplementary Fig. 12 and led to similar classiﬁcation to the results
presented in the main text Fig. 1. In addition, in the case of MOFA factors, in
accordance with Fig. 1, atypical carcinoids were stratiﬁed into a group with an
overall survival similar to that of the LCNEC (in red) and a group with a higher
overall survival (in pink), similar to that of the typical carcinoids. When using the
principal components, despite a similar trend, the difference in survival between
the high- and low-survival groups was not signiﬁcant. These results show that
dimensionality reduction does not lead to an increased classiﬁcation ability, nor
does it provide a better explanation of clinical behaviour. We thus chose to
represent only the results of the ML analyses based on expression and methylation
data in the main text and ﬁgures.
Survival analysis based on expression and methylation data. We divided
the samples into different groups based on the ML predictions. We represented
the Kaplan–Meier curves of the predictions groups by selecting the groups
with >10 samples and gathering the unclassiﬁed samples in the same group.
Using Cox’s proportional hazard model and using the logrank test statistic
(R package survival v2.42-3) we compared the overall survival of LCNEC, aty-
pical and typical samples based on the histopathological classiﬁcation and
based on the ML predictions (Supplementary Fig. 11A). Forest plots were drawn
using R package survminer (v0.4.3). The same survival analysis was performed
using the ML predictions based on MKI67 expression only (Supplementary
Fig. 11C).
Comparison between the supervised analyses of typical and atypical carci-
noids. We contrasted the results of the different supervised analyses between
typical and atypical carcinoids based on clinical data, speciﬁc markers (Ki67),
machine learning, differential expression, and differential methylation (Supple-
mentary Fig. 31). Survival analyses showed a signiﬁcant difference between his-
topathological types (Supplementary Fig. 31A). Nevertheless, the machine learning
classiﬁer based on the genome-wide expression or methylation data could not
properly distinguish atypical and typical carcinoids (Supplementary Fig. 31B): there
were 64–83% correctly classiﬁed typical carcinoids and only 30–41% correctly
classiﬁed atypical carcinoids. The differential expression analysis showed that
atypical carcinoids also presented very few core differentially expressed genes
(Supplementary Fig. 31C, middle panel and Supplementary Data 15) and differ-
entially methylated positions (Supplementary Fig. 31C, right panel and Supple-
mentary Data 17). Overall, these data suggest that the histopathological
classiﬁcation, although clinically meaningful, does not completely match the
molecular classiﬁcation.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The exome sequencing data, RNA-seq data, and methylation data have been deposited
in the European Genome-phenome Archive (EGA) database, which is hosted at the EBI
and the CRG, under accession number EGAS00001003699. Other data sets referenced
during the study are available from the EGA website under accession numbers
EGAS00001000650 (pulmonary carcinoids)11, EGAS00001000708 (LCNEC)12, and
EGAS00001000925 (SCLC)13,14. All the other data supporting the ﬁndings of this study
are available within the article and its supplementary information ﬁles and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information ﬁle.
Code availability
The code and software sources from previously published algorithms used to perform the
analyses are detailed in the supplementary tables and online methods. Custom scripts are
provided in the Supplementary Software 1. All sources for the software used in the
manuscript are summarised in Supplementary Data 18.
Received: 7 November 2018 Accepted: 2 July 2019
References
1. Travis, W. D. et al. The 2015 World Health Organization Classiﬁcation of lung
tumors: impact of genetic, clinical and radiologic advances since the 2004
classiﬁcation. J. Thorac. Oncol. 10, 1243–1260 (2015).
2. Rindi, G. et al. A common classiﬁcation framework for neuroendocrine
neoplasms: an International Agency for Research on Cancer (IARC) and
World Health Organization (WHO) expert consensus proposal. Modern
Pathol. 31:1770-1786 (2018).
3. Caplin, M. E. et al. Pulmonary neuroendocrine (carcinoid) tumors: European
Neuroendocrine Tumor Society expert consensus and recommendations for
best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 26,
1604–1620 (2015).
4. Swarts, D. R. et al. Interobserver variability for the WHO classiﬁcation of
pulmonary carcinoids. Am. J. Surg. Pathol. 38, 1429–1436 (2014).
5. Thunnissen, E. et al. The Use of immunohistochemistry improves the
diagnosis of small cell lung cancer and its differential diagnosis. An
international reproducibility study in a demanding set of cases. J. Thorac.
Oncol. 12, 334–346 (2017).
6. Marchio, C. et al. Distinctive pathological and clinical features of lung
carcinoids with high proliferation index. Virchows Arch. : Int. J. Pathol. 471,
713–720 (2017).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11276-9
18 NATURE COMMUNICATIONS |         (2019) 10:3407 | https://doi.org/10.1038/s41467-019-11276-9 | www.nature.com/naturecommunications
7. Pelosi, G., Rindi, G., Travis, W. D. & Papotti, M. Ki-67 antigen in lung
neuroendocrine tumors: unraveling a role in clinical practice. J. Thorac. Oncol.
9, 273–284 (2014).
8. Derks, J. L. et al. New insights into the molecular characteristics of pulmonary
carcinoids and large cell neuroendocrine carcinomas, and the impact on their
clinical management. J. Thorac. Oncol. 13, 752–766 (2018).
9. Pelosi, G. et al. Most high-grade neuroendocrine tumours of the lung are likely
to secondarily develop from pre-existing carcinoids: innovative ﬁndings
skipping the current pathogenesis paradigm. Virchows Arch. 472, 567–577
(2018).
10. Rekhtman, N. et al. Next-generation sequencing of pulmonary large cell
neuroendocrine carcinoma reveals small cell carcinoma-like and non-small
cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618–3629 (2016).
11. Fernandez-Cuesta, L. et al. Frequent mutations in chromatin-remodelling
genes in pulmonary carcinoids. Nat. Commun. 5, 3518 (2014).
12. George, J. et al. Integrative genomic proﬁling of large-cell neuroendocrine
carcinomas reveals distinct subtypes of high-grade neuroendocrine lung
tumors. Nat. Commun. 9, 1048 (2018).
13. Peifer, M. et al. Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer. Nat. Genet. 44, 1104–1110 (2012).
14. George, J. et al. Comprehensive genomic proﬁles of small cell lung cancer.
Nature 524, 47–53 (2015).
15. Argelaguet, R. et al. Multi-omics factor analysis-a framework for unsupervised
integration of multi-omics data sets. Mol. Syst. Biol. 14, e8124 (2018).
16. Straif, K. et al. A review of human carcinogens—Part C: metals, arsenic, dusts,
and ﬁbres. Lancet Oncol. 10, 453–454 (2009).
17. Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013).
18. Kiefer, J. et al. Abstract 3589: a systematic approach toward gene annotation of
the hallmarks of cancer. Cancer Res. 77, 3589–3589 (2017).
19. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
20. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and
inﬂammation. Nat. Rev. Immunol. 11, 762–774 (2011).
21. Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health
and inﬂammation. Nat. Rev. Immunol. 13, 159–175 (2013).
22. Jakubzick, C. V., Randolph, G. J. & Henson, P. M. Monocyte differentiation
and antigen-presenting functions. Nat. Rev. Immunol. 17, 349–362 (2017).
23. Cernadas, M., Lu, J., Watts, G. & Brenner, M. B. CD1a expression deﬁnes an
interleukin-12 producing population of human dendritic cells. Clin. Exp.
Immunol. 155, 523–533 (2009).
24. Odom, D. T. et al. Control of pancreas and liver gene expression by HNF
transcription factors. Science 303, 1378–1381 (2004).
25. Tran Janco, J. M., Lamichhane, P., Karyampudi, L. & Knutson, K. L. Tumor-
inﬁltrating dendritic cells in cancer pathogenesis. J. Immunol. 194, 2985–2991
(2015).
26. Gazdar, A. F., Bunn, P. A. & Minna, J. D. Small-cell lung cancer: what we
know, what we need to know and the path forward. Nat. Rev. Cancer 17, 765
(2017).
27. Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug
conjugate, in recurrent small-cell lung cancer: a ﬁrst-in-human, ﬁrst-in-class,
open-label, phase 1 study. Lancet Oncol. 18, 42–51 (2017).
28. Gara, R. K. et al. Slit/Robo pathway: a promising therapeutic target for cancer.
Drug Discov. Today 20, 156–164 (2015).
29. Boers, J. E., den Brok, J. L., Koudstaal, J., Arends, J. W. & Thunnissen, F. B.
Number and proliferation of neuroendocrine cells in normal human airway
epithelium. Am. J. Respir. Crit. Care Med. 154, 758–763 (1996).
30. Sutherland, K. D. & Berns, A. Cell of origin of lung cancer. Mol. Oncol. 4,
397–403 (2010).
31. Branchﬁeld, K. et al. Pulmonary neuroendocrine cells function as
airway sensors to control lung immune response. Science 351, 707–710
(2016).
32. Kimura, H. et al. Randomized controlled phase III trial of adjuvant chemo-
immunotherapy with activated killer T cells and dendritic cells in patients
with resected primary lung cancer. Cancer Immunol. Immunother.: CII 64,
51–59 (2015).
33. Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine
tumours. Nature 543, 65–71 (2017).
34. Simbolo, M. et al. Lung neuroendocrine tumours: deep sequencing of the four
World Health Organization histotypes reveals chromatin-remodelling genes
as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J.
Pathol. 241, 488–500 (2017).
35. Swarts, D. R. et al. CD44 and OTP are strong prognostic markers for
pulmonary carcinoids. Clin. Cancer Res. 19, 2197–2207 (2013).
36. Papaxoinis, G. et al. Prognostic signiﬁcance of CD44 and orthopedia
homeobox protein (OTP) expression in pulmonary carcinoid tumours.
Endocr. Pathol. 28, 60–70 (2017).
37. Koyama, T. et al. ANGPTL3 is a novel biomarker as it activates ERK/MAPK
pathway in oral cancer. Cancer Med. 4, 759–769 (2015).
38. Kurppa, K. J., Denessiouk, K., Johnson, M. S. & Elenius, K. Activating ERBB4
mutations in non-small cell lung cancer. Oncogene 35, 1283–1291 (2016).
39. Williams, C. S. et al. ERBB4 is over-expressed in human colon cancer and
enhances cellular transformation. Carcinogenesis 36, 710–718 (2015).
40. Fabbri, A. et al. Thymus neuroendocrine tumors with CTNNB1 gene
mutations, disarrayed ss-catenin expression, and dual intra-tumor Ki-67
labeling index compartmentalization challenge the concept of secondary high-
grade neuroendocrine tumor: a paradigm shift. Virchows Arch. 471, 31–47
(2017).
41. Wang, T. T. et al. Tumour-activated neutrophils in gastric cancer foster
immune suppression and disease progression through GM-CSF-PD-L1
pathway. Gut 66, 1900–1911 (2017).
42. Mojic, M., Takeda, K. & Hayakawa, Y. The dark side of IFN-gamma: its role in
promoting cancer immunoevasion. Int. J. Mol. Sci. 19, pii: E89 (2017).
43. Zaidi, M. R. & Merlino, G. The two faces of interferon-gamma in cancer. Clin.
Cancer Res. 17, 6118–6124 (2011).
44. Ocana, A., Nieto-Jimenez, C., Pandiella, A. & Templeton, A. J. Neutrophils in
cancer: prognostic role and therapeutic strategies. Mol. cancer 16, 137 (2017).
45. Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the
classiﬁcation of WHO grade 3 (G3) well-differentiated neuroendocrine tumor
(WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC)
of the pancreas. Am. J. Surg. Pathol. 40, 1192–1202 (2016).
46. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.)
57, 289–300 (1995).
47. Di Tommaso, P. et al. Nextﬂow enables reproducible computational
workﬂows. Nat. Biotechnol. 35, 316–319 (2017).
48. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
49. Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and
structural variant read extraction. Bioinformatics 30, 2503–2505 (2014).
50. Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast
processing of NGS alignment formats. Bioinformatics 31, 2032–2034 (2015).
51. Mose, L. E., Wilkerson, M. D., Hayes, D. N., Perou, C. M. & Parker, J. S.
ABRA: improved coding indel detection via assembly-based realignment.
Bioinformatics 30, 2813–2815 (2014).
52. Delhomme, T. M. et al. needlestack: an ultra-sensitive variant caller for multi-
sample deep next generation sequencing data. bioRxiv https://doi.org/10.1101/
639377 (2019).
53. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucl. Acids Res. 38,
e164 (2010).
54. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
55. Dobin, A. & Gingeras, T. R. Mapping RNA-seq Reads with STAR. Curr. Proto.
Bioinforma. 51, 11.14.11-19, https://doi.org/10.1002/0471250953.bi1114s51
(2015).
56. Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with
high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
57. Pertea, M., Kim, D., Pertea, G. M., Leek, J. T. & Salzberg, S. L. Transcript-level
expression analysis of RNA-seq experiments with HISAT, StringTie and
Ballgown. Nat. Protoc. 11, 1650–1667 (2016).
58. Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize
analysis results for multiple tools and samples in a single report.
Bioinformatics 32, 3047–3048 (2016).
59. Fernandez-Cuesta, L. et al. Identiﬁcation of novel fusion genes in lung cancer
using breakpoint assembly of transcriptome sequencing data. Genome Biol. 16,
7 (2015).
60. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
61. Dray, S. & Dufour, A. B. The ade4 package: implementing the duality diagram
for ecologists. J. Stat. Softw. 22, 20 (2007).
62. Finotello, F. et al. Molecular and pharmacological modulators of the tumor
immune contexture revealed by deconvolution of RNA-seq data. Genome
Med. 11, 34 (2019).
63. Aryee, M. J. et al. Minﬁ: a ﬂexible and comprehensive Bioconductor package
for the analysis of Inﬁnium DNA methylation microarrays. Bioinformatics 30,
1363–1369 (2014).
64. Xu, Z., Niu, L., Li, L. & Taylor, J. A. ENmix: a novel background correction
method for Illumina HumanMethylation450 BeadChip. Nucl. Acids Res. 44,
e20 (2016).
65. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucl. Acids Res. 43, e47 (2015).
66. Mo, Q. et al. Pattern discovery and cancer gene identiﬁcation in integrated
cancer genomic data. Proc. Natl Acad. Sci. USA 110, 4245–4250 (2013).
67. Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool
with conﬁdence assessments and item tracking. Bioinformatics 26, 1572–1573
(2010).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11276-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3407 | https://doi.org/10.1038/s41467-019-11276-9 | www.nature.com/naturecommunications 19
68. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identiﬁers for
the integration of genomic datasets with the R/Bioconductor package
biomaRt. Nat. Protoc. 4, 1184–1191 (2009).
69. Zhang, J. D. & Wiemann, S. KEGGgraph: a graph approach to KEGG
PATHWAY in R and bioconductor. Bioinformatics 25, 1470–1471 (2009).
70. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized
linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
Acknowledgements
We thank the patients donating their tumour specimens. We also thank Prof. Roman K.
Thomas, Dr. Martin Peifer, Dr. Julie George, Dr. Paul Brennan, and Dr. Ghislaine Scelo for
their help with logistics. We also thank Dr. Ricard Argelaguet for his advice in using MOFA.
This study is part of the lungNENomics project and the Rare Cancers Genomics initiative
(www.rarecancersgenomics.com). This work has been funded by the US National Institutes
of Health (NIH R03CA195253 to L.F.C. and J.D.M.), the French National Cancer Institute
(INCa, PRT-K-17-047 to L.F.C. and TABAC 17-022 to J.D.M.), the Ligue Nationale contre
le Cancer (LNCC 2016 to L.F.C.), France Genomique (to J.D.M.), and the Italian Asso-
ciation for Cancer Research (AIRC) (IG 19238 to M.V. and MFAG 12983 to L.A.M.)
(Special Programme 5X1000, ED No12162 to U.P., L.R., and G.S.). J.S. is a Miguel Servet
researcher (CP13/00055 and PI16/0295). L.M. and T.M.D. have fellowships from the LNCC.
Author contributions
L.F.C. conceived and designed the study. L.F.C. and M.F. supervised all the aspects of the
study. A.G., A.B., J.A., F.L.C.K., S.B., J.S., N.G. and S.Lan. supervised some aspects of the
study. B.A.A., E.B. and S.Lan. performed the histopathological review. N.Leb., T.G., J.D.,
A.C., C. Cu., G.D. and N.Lem. did the lab work. N.A., N.Leb., A.A.G.G., L.M., D.H.,
A.S.S., A.F., T.M.D., R.O., V.M., C.V. and L.A.M. performed the computational and
statistical analyses. P.L., A.C.T., A.S., J.H.C., J. Saenger, J. Stojsic, J.K.F., M.B., C.B.F.,
F.G.S., N.L.S., P.A.R., G.W., L.R., G.S., U.P., M.M., S.Lac., J.M.V., V.H., P.H., O.T.B.,
M.L.-I., V.T.M., L.A.M., P.G., M.V., M.G.P., L.B., H.P., A.M.C.D., E.B., E.J.M.S., N.G. and
S.Lan contributed with samples and the corresponding histopathological, epidemiolo-
gical, and clinical data. J.F.D., Z.H., A.V., P.N. and J.D.M. helped with logistics. J.D., B.A.
A., C. Ca., L.R., M.M., M.V., M.G.P., L.B., H.P., G.P., J.D.M., H.H.V., E.J.M.S., N.G. and
S.Lan gave scientiﬁc input. N.A., N.Leb., A.A.G.G., L.M., J.D.M., M.F. and
L.F.C. wrote the manuscript, which was reviewed and commented by all the co-authors.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-11276-9.
Competing interests: The authors declare no competing interests. Where authors are
identiﬁed as personnel of the International Agency for Research on Cancer/World
Health Organisation, the authors alone are responsible for the views expressed in this
article and they do not necessarily represent the decisions, policy or views of the
International Agency for Research on Cancer/World Health Organisation.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks Florian Buettner and Takashi
Kohno for their contribution to the peer review of this work. Peer reviewer reports are
available
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
N. Alcala 1,35, N. Leblay1,35, A.A.G. Gabriel1,35, L. Mangiante1, D. Hervas2, T. Giffon 1, A.S. Sertier3, A. Ferrari3,
J. Derks 4, A. Ghantous5, T.M. Delhomme 1, A. Chabrier1, C. Cuenin5, B. Abedi-Ardekani1, A. Boland6,
R. Olaso6, V. Meyer6, J. Altmuller7, F. Le Calvez-Kelm1, G. Durand1, C. Voegele1, S. Boyault 8, L. Moonen4,
N. Lemaitre9, P. Lorimier9, A.C. Toffart10, A. Soltermann11, J.H. Clement 12, J. Saenger13, J.K. Field 14,
M. Brevet 15, C. Blanc-Fournier16, F. Galateau-Salle17, N. Le Stang 17, P.A. Russell18, G. Wright 18, G. Sozzi19,
U. Pastorino19, S. Lacomme20, J.M. Vignaud20, V. Hofman21, P. Hofman21, O.T. Brustugun22,23,
M. Lund-Iversen 23, V. Thomas de Montpreville24, L.A. Muscarella25, P. Graziano 25, H. Popper 26,
J. Stojsic 27, J.F. Deleuze6, Z. Herceg5, A. Viari3, P. Nuernberg7,28, G. Pelosi 29, A.M.C. Dingemans4,
M. Milione19, L. Roz 19, L. Brcic 26, M. Volante30, M.G. Papotti30, C. Caux31, J. Sandoval2,
H. Hernandez-Vargas 32, E. Brambilla9, E.J.M. Speel4, N. Girard33,34, S. Lantuejoul3,8,17, J.D. McKay1, M. Foll1 &
L. Fernandez-Cuesta 1
1International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008 Lyon, France. 2Health Research
Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026 Valencia, Spain. 3Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue
Laennec, 69008 Lyon, France. 4Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box
5800, 6202 AZMaastricht, The Netherlands. 5International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of
Carcinogenesis, 150 Cours Albert Thomas, 69008 Lyon, France. 6Centre National de Recherche en Génomique Humaine (CNRGH), Institut de
Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057 Evry Cedex, France. 7Cologne Centre for Genomics
(CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931 Cologne, Germany. 8Translational
Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008 Lyon, France. 9Institute for Advanced Biosciences, Site
Santé, Allée des Alpes, 38700 La Tronche, Grenoble, France. 10Pulmonology—Physiology Unit, Grenoble Alpes University Hospital, 38700 La
Tronche, France. 11Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.
12Department Hematology and Medical Oncology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany. 13Bad Berka Institute of
Pathology, Robert-Koch-Allee 9, 99438 Bad Berka, Germany. 14Roy Castle Lung Cancer Research Programme, Department of Molecular and
Clinical Cancer Medicine, University of Liverpool, 6 West Derby Street, L7 8TX Liverpool, UK. 15Pathology Institute, Hospices Civils de Lyon,
University Claude Bernard Lyon 1, 59 Boulevard Pinel, 69677 BRON Cedex, France. 16CLCC François Baclesse, 3 avenue du Général Harris, 14076
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11276-9
20 NATURE COMMUNICATIONS |         (2019) 10:3407 | https://doi.org/10.1038/s41467-019-11276-9 | www.nature.com/naturecommunications
Caen Cedex 5, France. 17Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373 Lyon Cedex 8, France. 18St. Vincent’s Hospital and
University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC 3065, Australia. 19Pathology Division Fondazione, IRCCS Istituto Nazionale dei
Tumori, Via G. Venezian 1, 20133 Milan, Italy. 20Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du
Maréchal de Lattre de Tassigny, 54035 Nancy Cedex, France. 21Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital,
Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d’Azur, 30 avenue de la voie Romaine, CS, 51069-06001 Nice Cedex
1, France. 22Drammen Hospital, Vestre Viken Health Trust, Vestre Viken HF, Postboks 800, 3004 Drammen, Norway. 23Institute of Cancer
Research, Oslo University Hospital, Ullernchausseen 70, 0379 Oslo, Norway. 24Marie Lannelongue Hospital, 133 avenue de la Resistance, 92350 Le
Plessis Robinson, France. 25Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013 San Giovanni Rotondo FG, Italy.
26Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria. 27Department of
Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Pasterova 2, Belgrade 11000, Serbia. 28Cologne Excellence Cluster on
Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Straße 26, 50931 Cologne, Germany.
29Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Via Gaudenzio
Fantoli, 16/15, 20138 Milan, Italy. 30Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126 Torino, Italy.
31Department of Immunity, Virus, and Inﬂammation, Cancer Research Centre of Lyon (CRCL), 28 Rue Laennec, 69008 Lyon, France. 32Cancer
Research Centre of Lyon (CRCL), Inserm U 1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, 28 Rue Laennec, 69008 Lyon, France.
33Institut Curie, 26 Rue d’Ulm, 75005 Paris, France. 34European Reference Network (ERN-EURACAN), 28 rue Laennec, 69008 Lyon, France.
35These authors contributed equally: Alcala N., Leblay N., Gabriel A. A. G. 36These authors jointly supervised this work: Foll M., Fernandez-Cuesta L.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11276-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3407 | https://doi.org/10.1038/s41467-019-11276-9 | www.nature.com/naturecommunications 21
